← For Researchers/Lp(a)/Research Sites

Lp(a) Research Sites

Sites currently running trials · ranked by activity

Endometriosis Long COVID ALS PTSD Sickle Cell Disease Lupus Prostate Cancer Menopause Lp(a)

2642 sites · 3263 trials · August 2026

Recruiting

Opening soon

Active · not recruiting

National Heart Institute

Beverly Hills · California · United States

5 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Jacksonville Center for Clinical Research

Jacksonville · Florida · United States

5 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Intermountain Medical Center

Murray · Utah · United States

5 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Virginia Heart

Falls Church · Virginia · United States

5 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Anderson Medical Research

Ft. Washington · Maryland · United States

4 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Novartis Investigative Site

Beijing · China

4 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Inclisiran drug tested to shrink heart artery plaque in heart attack patients with high cholesterol.

Novartis PharmaceuticalsPh 4NCT06372925 ↗

Inclisiran drug safety and effectiveness evaluated in young children with severe inherited high cholesterol.

Novartis PharmaceuticalsPh 3RecruitingNCT06597006 ↗

Advara HeartCare Joondalup

Joondalup · Australia

4 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

Eclipse Clinical Research

Tucson · Arizona · United States

3 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

Peace River Cardiovascular Center

Port Charlotte · Florida · United States

3 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Johns Hopkins University

Columbia · Maryland · United States

3 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

Henry Ford Hospital

Detroit · Michigan · United States

3 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Xian · Shanxi · China

3 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Inclisiran drug tested to shrink heart artery plaque in heart attack patients with high cholesterol.

Novartis PharmaceuticalsPh 4NCT06372925 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Taipei · Taiwan

3 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

Inclisiran drug safety and effectiveness evaluated in young children with severe inherited high cholesterol.

Novartis PharmaceuticalsPh 3RecruitingNCT06597006 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3ActiveNCT06813911 ↗

Vector Clinical Trials

Las Vegas · Nevada · United States

3 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Eastside Research Associates

Redmond · Washington · United States

3 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Nightingale Research

Adelaide · Australia

3 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Advara HeartCare Leabrook

Leabrook · Australia

3 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

USC Clinical Trials Brisbane (South Bank)

South Brisbane · Australia

3 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

Clinitrials

West Perth · Australia

3 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

Semmelweis University

Budapest · Hungary

3 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

CHUAC-Complejo Hospitalario Universitario A Coruña

A Coruña · Spain

3 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Parc de Salut Mar - Hospital del Mar

Barcelona · Spain

3 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Hospital Universitario Reina Sofia

Córdoba · Spain

3 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Hospital Universitario Ramón y Cajal

Madrid · Spain

3 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Hospital Universitario Virgen Del Rocio

Seville · Spain

3 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Hospital General Universitario de Valencia

Valencia · Spain

3 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Bristol Royal Infirmary

Bristol · United Kingdom

3 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Rainier Clinical Research Center

Renton · Washington · United States

3 trials

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

Excel Medical Clinical Trials

Boca Raton · Florida · United States

3 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

North Georgia Clinical Research

Woodstock · Georgia · United States

3 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

Ascension Saint Agnes Heart Care

Baltimore · Maryland · United States

3 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

Walker Family Care

Little River · South Carolina · United States

3 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

Victorian Heart Hospital

Clayton · Australia

3 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

Fusion Clinical Research

Norwood · Australia

3 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

Ecogene-21

Chicoutimi · Canada

3 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

North York Diagnostic and Cardiac Centre

North York · Canada

3 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

Victoria Heart Institute Foundation

Victoria · Canada

3 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

Peking University First Hospital

Beijing · Beijing Municipality · China

2 trials

Oral SAL0137 drug tested to lower lipoprotein(a) and reduce heart disease risk in high-risk adults.

Shenzhen Salubris Pharmaceuticals Co., Ltd.Ph 2NCT07729475 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Heart Center Research Llc

Huntsville · Alabama · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

Mobile Heart Specialists

Mobile · Alabama · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Mercy Gilbert Medical Center

Gilbert · Arizona · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Clinical Research Inst of Arizona

Sun City West · Arizona · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Valley Clinical Trials

Northridge · California · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

Manshadi Heart Institute

Stockton · California · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

Interv Cardiology Med Grp

West Hills · California · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Bridgeport Hospital

Bridgeport · Connecticut · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Chase Medical Research LLC

Waterbury · Connecticut · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

Excel Medical Clinical Trials LLC

Boca Raton · Florida · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3ActiveNCT06813911 ↗

Progressive Medical Research

Port Orange · Florida · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Advocate Lutheran General Childrens Hospital

Park Ridge · Illinois · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Cardiovascular Associates Research

Covington · Louisiana · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Omega Clinical Research

Metairie · Louisiana · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

University Of Minnesota

Minneapolis · Minnesota · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

StudyMetrix Research

City of Saint Peters · Missouri · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Washington Univ School Of Medicine

St Louis · Missouri · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Inclisiran drug safety and effectiveness evaluated in young children with severe inherited high cholesterol.

Novartis PharmaceuticalsPh 3RecruitingNCT06597006 ↗

Overlook Medical Center

Summit · New Jersey · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Lenox Hill Hospital

New York · New York · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Northwell Health Physician Peconic

Riverhead · New York · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Medication Management LLC

Greensboro · North Carolina · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

Wake Forest University Baptist Medical Center

Winston-Salem · North Carolina · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Ohio State University

Columbus · Ohio · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Monument Health Clinical Research

Rapid City · South Dakota · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

Baylor College Of Medicine

Houston · Texas · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

Northwest Houston Clinical Research PLLC

Tomball · Texas · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Carient Heart and Vascular

Manassas · Virginia · United States

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

Novartis Investigative Site

Vienna · Austria

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

Inclisiran drug safety and effectiveness evaluated in young children with severe inherited high cholesterol.

Novartis PharmaceuticalsPh 3RecruitingNCT06597006 ↗

Novartis Investigative Site

Lanzhou · Gansu · China

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Inclisiran drug tested to shrink heart artery plaque in heart attack patients with high cholesterol.

Novartis PharmaceuticalsPh 4NCT06372925 ↗

Novartis Investigative Site

Guangzhou · Guangdong · China

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Inclisiran drug tested to shrink heart artery plaque in heart attack patients with high cholesterol.

Novartis PharmaceuticalsPh 4NCT06372925 ↗

Novartis Investigative Site

Harbin · Heilongjiang · China

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Inclisiran drug tested to shrink heart artery plaque in heart attack patients with high cholesterol.

Novartis PharmaceuticalsPh 4NCT06372925 ↗

Novartis Investigative Site

Changchun · Jilin · China

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Inclisiran drug tested to shrink heart artery plaque in heart attack patients with high cholesterol.

Novartis PharmaceuticalsPh 4NCT06372925 ↗

Novartis Investigative Site

Dalian · Liaoning · China

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Inclisiran drug tested to shrink heart artery plaque in heart attack patients with high cholesterol.

Novartis PharmaceuticalsPh 4NCT06372925 ↗

Novartis Investigative Site

Chengdu · Sichuan · China

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Inclisiran drug tested to shrink heart artery plaque in heart attack patients with high cholesterol.

Novartis PharmaceuticalsPh 4NCT06372925 ↗

Novartis Investigative Site

Wenzhou · Zhejiang · China

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Inclisiran drug tested to shrink heart artery plaque in heart attack patients with high cholesterol.

Novartis PharmaceuticalsPh 4NCT06372925 ↗

Novartis Investigative Site

Shanghai · China

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Tianjin · China

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

Inclisiran drug tested to shrink heart artery plaque in heart attack patients with high cholesterol.

Novartis PharmaceuticalsPh 4NCT06372925 ↗

Novartis Investigative Site

Grenoble · France

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3ActiveNCT06813911 ↗

Novartis Investigative Site

Paris · France

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Toulouse · France

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Mannheim · Germany

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Frankfurt am Main · Hesse · Germany

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Inclisiran drug safety and effectiveness evaluated in young children with severe inherited high cholesterol.

Novartis PharmaceuticalsPh 3RecruitingNCT06597006 ↗

Novartis Investigative Site

Chemnitz · Saxony · Germany

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Leipzig · Saxony · Germany

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Berlin · Germany

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Bielefeld · Germany

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Gelnhausen · Germany

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Münster · Germany

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Potsdam · Germany

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Ioannina · Greece

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Inclisiran drug safety and effectiveness evaluated in young children with severe inherited high cholesterol.

Novartis PharmaceuticalsPh 3RecruitingNCT06597006 ↗

Novartis Investigative Site

Thessaloniki · Greece

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Inclisiran drug safety and effectiveness evaluated in young children with severe inherited high cholesterol.

Novartis PharmaceuticalsPh 3RecruitingNCT06597006 ↗

Novartis Investigative Site

Hong Kong · Hong Kong

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Ancona · AN · Italy

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Milan · MI · Italy

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Rozzano · MI · Italy

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Perugia · PG · Italy

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Salerno · SA · Italy

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Amsterdam · North Holland · Netherlands

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Inclisiran drug safety and effectiveness evaluated in young children with severe inherited high cholesterol.

Novartis PharmaceuticalsPh 3RecruitingNCT06597006 ↗

Novartis Investigative Site

The Hague · South Holland · Netherlands

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

Santiago Compostela · A Coruna · Spain

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Novartis Investigative Site

A Coruña · Spain

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

100

Novartis Investigative Site

Barcelona · Spain

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

101

Novartis Investigative Site

Córdoba · Spain

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

102

Novartis Investigative Site

Huelva · Spain

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

103

Novartis Investigative Site

Taichung · Taiwan ROC · Taiwan

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

Inclisiran drug safety and effectiveness evaluated in young children with severe inherited high cholesterol.

Novartis PharmaceuticalsPh 3RecruitingNCT06597006 ↗

104

Novartis Investigative Site

Kaohsiung City · Taiwan

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

105

Novartis Investigative Site

Tainan · Taiwan

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

106

Novartis Investigative Site

Izmir · Turkey (Türkiye)

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Inclisiran drug safety and effectiveness evaluated in young children with severe inherited high cholesterol.

Novartis PharmaceuticalsPh 3RecruitingNCT06597006 ↗

107

Novartis Investigative Site

Ankara · Bilkent-Cankaya · Turkey (Türkiye)

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Inclisiran drug safety and effectiveness evaluated in young children with severe inherited high cholesterol.

Novartis PharmaceuticalsPh 3RecruitingNCT06597006 ↗

108

Novartis Investigative Site

London · United Kingdom

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

109

Novartis Investigative Site

Chichester · West Sussex · United Kingdom

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

110

Novartis Investigative Site

Manchester · United Kingdom

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

111

Novartis Investigative Site

Tyne and Wear · United Kingdom

2 trials

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

112

UCSD - Altman Clinical and Translational Research Institute (ACTRI)

La Jolla · California · United States

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

113

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Torrance · California · United States

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

114

Jellinger and Lerman, MD PA dba The Center for Diabetes and Endocrine Care

Fort Lauderdale · Florida · United States

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

115

Inpatient Research Clinic

Miami Lakes · Florida · United States

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

116

CARE Institute - High Desert

Meridian · Idaho · United States

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

117

Heart and Vascular Research at WellSpan Health

York · Pennsylvania · United States

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

118

Carilion Clinic

Roanoke · Virginia · United States

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

119

Core Research Group

Brisbane · Australia

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

120

Advara HeartCare - Burwood

Burwood · Australia

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

121

AIM Research

Merewether · Australia

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

122

Advara HeartCare - Mulgrave

Mulgrave · Australia

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

123

Fakultni Nemocnice u sv. Anny v Brne

Brno · Czechia

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

124

EFERTUS healthcare s.r.o.

Brno · Czechia

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

125

Óbudai Egészségügyi Centrum

Budapest · Hungary

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

126

Ziekenhuis St. Jansdal

Harderwijk · Netherlands

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

127

VieCuri Medisch Centrum, locatie Venlo

Venlo · Netherlands

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

128

Hospital Insular de Gran Canaria

Las Palmas de Gran Canaria · Spain

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

129

Hospital Clinico San Carlos

Madrid · Spain

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

130

Hospital Universitario Virgen Macarena

Seville · Spain

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

131

Cheadle Community Hospital

Cheadle · United Kingdom

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

132

Lister Hospital

Stevenage · United Kingdom

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

133

FutureMeds Teesside - Middlefield Centre

Stockton-on-Tees · United Kingdom

2 trials

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

134

Novartis Investigative Site

Jining · Shandong · China

2 trials

Inclisiran drug tested to shrink heart artery plaque in heart attack patients with high cholesterol.

Novartis PharmaceuticalsPh 4NCT06372925 ↗

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

135

Mercury Street Medical Group, PLLC

Butte · Montana · United States

2 trials

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

136

Altoona Center for Clinical Research

Duncansville · Pennsylvania · United States

2 trials

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

137

Endeavor Clinical Trials

San Antonio · Texas · United States

2 trials

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

138

Consano Clinical Research, LLC

Shavano Park · Texas · United States

2 trials

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

139

Birmingham Clinical Research

Birmingham · Alabama · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

140

Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC

Gilbert · Arizona · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

141

Clinical Research Institute of Arizona (CRI) - Sun City West

Sun City West · Arizona · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

142

Pima Heart

Tucson · Arizona · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

143

Neighborhood Healthcare Institute of Health

Escondido · California · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

144

Care Access - Huntington Beach

Huntington Beach · California · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

145

310 Clinical Research

Inglewood · California · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

146

Scripps Whittier Diabetes Institute

La Jolla · California · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

147

UCLA South Bay Endocrinology

Torrance · California · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

148

Interventional Cardiology Medical Group

West Hills · California · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

149

University of Colorado Anschutz Medical Campus

Aurora · Colorado · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

150

Cardiology Associates of Fairfield County, P.C.

Stamford · Connecticut · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

151

Chase Medical Research, LLC

Waterbury · Connecticut · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

152

K2 Medical Research - Maitland

Maitland · Florida · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

153

Advanced Research for Health Improvement, LLC

Naples · Florida · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

154

Renstar Medical Research

Ocala · Florida · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

155

Care Access - Tamarac

Tamarac · Florida · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

156

Care Access - Tampa

Tampa · Florida · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

157

Southeastern Clinical Research Institute

Augusta · Georgia · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

158

Center for Advanced Research & Education

Gainesville · Georgia · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

159

Great Lakes Clinical Trials - Ravenswood

Chicago · Illinois · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

160

Clinical Investigation Specialists

Gurnee · Illinois · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

161

Indiana University Health Methodist Hospital

Indianapolis · Indiana · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

162

IMA Clinical Research

Monroe · Louisiana · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

163

Flourish Research - Bowie

Bowie · Maryland · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

164

Brigham and Women's Hospital Diabetes Program

Boston · Massachusetts · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

165

Care Access - Quincy

Quincy · Massachusetts · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

166

Revival Research Institute, LLC

Dearborn · Michigan · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

167

Arcturus Healthcare , PLC, Troy Internal Medicine Research Division

Troy · Michigan · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

168

Cardio Metabolic Institute

Somerset · New Jersey · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

169

IMA Clinical Research

Albuquerque · New Mexico · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

170

Icahn School of Medicine at Mount Sinai

New York · New York · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

171

IMA Clinical Research Manhattan

New York · New York · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

172

Care Access - Fayetteville

Fayetteville · North Carolina · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

173

Medication Management

Greensboro · North Carolina · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

174

Lehigh Valley Health Network

Allentown · Pennsylvania · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

175

Capital Area Research, LLC

Camp Hill · Pennsylvania · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

176

Penn Medicine: University of Pennsylvania Health System

Philadelphia · Pennsylvania · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

177

Clinical Research of Philadelphia

Philadelphia · Pennsylvania · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

178

Keystone Clinical Studies

Plymouth Meeting · Pennsylvania · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

179

Cardiology Consultants of Philadelphia Yardley

Yardley · Pennsylvania · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

180

PharmaTex Research

Amarillo · Texas · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

181

Velocity Clinical Research, Austin

Austin · Texas · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

182

Zenos Clinical Research

Dallas · Texas · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

183

UT Southwestern Medical Center

Dallas · Texas · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

184

Texas Health Research & Education Institute - Fort Worth

Fort Worth · Texas · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

185

Center for Cardiometabolic Disease Prevention/Baylor College of Medicine

Houston · Texas · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

186

Research Physicians Network, LLC

Houston · Texas · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

187

Biopharma Informatic, LLC

McAllen · Texas · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

188

Revival Research Institute, LLC

McKinney · Texas · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

189

PRX Research

Mesquite · Texas · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

190

IMA Clinical Research San Antonio

San Antonio · Texas · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

191

Sherman Clinical Research

Sherman · Texas · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

192

Clinical Investigation Specialists

Kenosha · Wisconsin · United States

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

193

Buenos Aires Macula S.A

Buenos Aires · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

194

Instituto Médico Especializado (IME)

Buenos Aires · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

195

Consultorio Medico Dr Litvak Bruno

Buenos Aires · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

196

Consultorio Medico Investigador Principal Dr Besada

Buenos Aires · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

197

Stat Research S.A.

Buenos Aires · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

198

Investigaciones Medicas Imoba Srl

Buenos Aires · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

199

Centro de Investigaciones Metabólicas (CINME)

Buenos Aires · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

200

CIPREC

Buenos Aires · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

201

CEMEDIC

Buenos Aires · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

202

Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada

Buenos Aires · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

203

Fundación Respirar

Buenos Aires · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

204

Centro Médico Arsema

Buenos Aires · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

205

Glenny Corp. S.A.

Buenos Aires · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

206

IDIM - Instituto de Investigaciones Metabólicas

Ciudad de Buenos Aires · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

207

Instituto de Cardiología "Juana F. Cabral"

Corrientes · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

208

Instituto de Investigaciones Clínicas Córdoba

Córdoba · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

209

Centro Médico Colón

Córdoba · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

210

CIPADI - Centro Integral de Prevencion y Atencion en Diabetes

Godoy Cruz · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

211

Centro de Investigaciones Clínicas Baigorria

Granadero Baigorria · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

212

CIMeL

Lanus · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

213

Centro de Investigaciones Médicas Mar del Plata

Mar del Plata · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

214

Instituto de Investigaciones Clínicas Mar del Plata

Mar del Plata · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

215

Instituto de Cardiología Wolff

Mendoza · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

216

Instituto De Investigaciones Clinicas Quilmes

Quilmes · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

217

DIM Clínica Privada

Ramos Mejía · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

218

Instituto Médico Río Cuarto

Río Cuarto · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

219

Fundacion Estudios Clinicos

Rosario · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

220

INECO Neurociencias Oroño

Rosario · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

221

Instituto Especialidades de la Salud Rosario

Rosario · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

222

Instituto Médico Catamarca IMEC

Rosario · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

223

Instituto de Investigaciones Clinicas Rosario

Rosario · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

224

Laboratorio de Hemostasia y Trombosis

Rosario · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

225

Hospital Provincial del Centenario

Rosario · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

226

Corporación Médica San Martín

San Martin · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

227

Centro Modelo de Cardiología

San Miguel de Tucumán · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

228

Investigaciones Clínicas Tucumán

San Miguel de Tucumán · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

229

Centro de Diagnóstico y Rehabilitación (CEDIR)

Santa Fe · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

230

Centro de Investigaciones Clinicas del Litoral

Santa Fe · Argentina

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

231

Box Hill Hospital

Box Hill · Australia

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

232

Royal Brisbane and Women's Hospital

Brisbane · Australia

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

233

Heart of Australia

Brisbane · Australia

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

234

Cholesterol Care

Brisbane · Australia

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

235

Barwon Health

Geelong · Australia

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

236

University of the Sunshine Coast (UniSC) Clinical Trials - Meadowbrook

Meadowbrook · Australia

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

237

The AIM Centre / Hunter Diabetes Centre

Merewether · Australia

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

238

USC Clinical Trials Moreton Bay

Morayfield · Australia

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

239

USC Clinical Trials Sunshine Coast

Sippy Downs · Australia

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

240

Krankenhaus St. Josef Braunau

Braunau am Inn · Austria

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

241

VIVIT

Feldkirch · Austria

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

242

Ordensklinikum Linz GmbH Elisabethinen

Linz · Austria

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

243

Konventhospital der Barmherzigen Brüder Linz

Linz · Austria

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

244

Landesklinikum Mistelbach

Mistelbach · Austria

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

245

Uniklinikum Salzburg

Salzburg · Austria

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

246

Universitätsklinikum St. Pölten

Sankt Pölten · Austria

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

247

Klinik Landstraße

Vienna · Austria

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

248

Zentrum für klinische Studien Dr Hanusch Gmbh

Vienna · Austria

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

249

Medizinische Universität Wien

Vienna · Austria

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

250

Universitaetsklinikum Allgemeines Krankenhaus Wien

Vienna · Austria

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

251

Klinik Hietzing

Vienna · Austria

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

252

Herz Zentrum Währing - Innere Medizin und Kardiologie | Alle Kassen und Privat

Vienna · Austria

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

253

Klinik Floridsdorf

Vienna · Austria

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

254

ZAS Middelheim

Antwerp · Belgium

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

255

Imelda General Hospital

Bonheiden · Belgium

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

256

Algemeen Ziekenhuis klina

Brasschaat · Belgium

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

257

Centre Hospitalier Universitaire Brugmann

Brussels · Belgium

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

258

Cliniques universitaires Saint-Luc

Brussels · Belgium

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

259

Antwerp University Hospital

Edegem · Belgium

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

260

Ziekenhuis Oost-Limburg, Campus St.-Jan

Genk · Belgium

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

261

AZ Groeninge Campus Kennedylaan

Kortrijk · Belgium

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

262

UZ Leuven

Leuven · Belgium

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

263

AZ Sint-Maarten

Mechelen · Belgium

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

264

AZ Oostende vzw

Ostend · Belgium

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

265

AZ Delta vzw

Roeselare · Belgium

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

266

Centro de Pesquisa Clinica do Coracao

Aracaju · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

267

Hospital Universitário João de Barros Barreto

Belém · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

268

NUPEC - Cardio

Belo Horizonte · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

269

AngioKormann Blumenau

Blumenau · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

270

Chronos Pesquisa Clínica

Brasília · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

271

Instituto de Pesquisa clinica de Campinas

Campinas · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

272

Centro de Pesquisa Sao Lucas

Campinas · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

273

Quanta Diagnóstico e Terapia

Curitiba · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

274

Universidade Federal de Goias

Goiânia · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

275

Instituto Do Coracao De Marilia

Marília · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

276

Instituto Méderi de Pesquisa e Saúde

Passo Fundo · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

277

Hospital de Clinicas de Porto Alegre

Porto Alegre · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

278

Hospital Moinhos de Vento

Porto Alegre · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

279

Núcleo de Pesquisa Clínica do Rio Grande do Sul

Porto Alegre · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

280

Hospital Nossa Senhora da Conceição

Porto Alegre · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

281

IBPClin - Instituto Brasil de Pesquisa Clínica

Rio de Janeiro · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

282

Ruschel Medicina e Pesquisa Clínica

Rio de Janeiro · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

283

Praxis Pesquisa Medica

Santo André · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

284

Fundação Faculdade Regional de Medicina de São José do Rio Preto

São José do Rio Preto · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

285

Centro Internacional de Pesquisa Clínica (CIPES)

São José dos Campos · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

286

CPQuali Pesquisa Clínica

São Paulo · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

287

CPCLIN

São Paulo · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

288

Instituto Dante Pazzanese de Cardiology

São Paulo · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

289

CEPIC - Centro Paulista de Investigação Clínica

São Paulo · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

290

Incor - Instituto do Coracao

São Paulo · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

291

CEDOES

Vitória · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

292

Integral Pesquisa e Ensino

Votuporanga · Brazil

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

293

Premier Clinical Trial Network

Hamilton · Canada

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

294

Diex Recherche Inc. Division Joliette

Joliette · Canada

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

295

Viacar Recherche Clinique

Longueuil · Canada

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

296

G A Research Associates

Moncton · Canada

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

297

Diex Recherche Inc. Division Trois-Rivieres

Trois-Rivières · Canada

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

298

Discovery Clinical Services

Victoria · Canada

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

299

Peking University Third Hospital

Beijing · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

300

The First Hospital of Jilin University

Changchun · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

301

China-Japan Union Hospital

Changchun · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

302

Changde First People's Hospital

Changde · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

303

Sichuan Provincial People's Hospital

Chengdu · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

304

West China Hospital Sichuan University

Chengdu · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

305

2nd Affiliated Hospital Chongqing Medical Universi

Chongqing · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

306

Guangdong Provincial People's Hospital

Guangzhou · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

307

Zhejiang Provincial People's Hospital

Hangzhou · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

308

The First Hospital of Harbin Medical University

Harbin · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

309

The Second People's Hospital of Hefei

Hefei · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

310

Jinan Central Hospital

Jinan · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

311

Lishui Central Hospital

Lishui · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

312

The First Affiliated Hospital of Henan University of Science &Technology

Luoyang · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

313

Zhongshan Hospital,Fudan University

Shanghai · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

314

Siping Central People's Hospital

Siping · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

315

Chongqing Three Gorges Central Hospital

Wanzhou · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

316

Renmin Hospital of Wuhan University

Wuhan · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

317

Shaanxi provincial people's hospital

Xi'an · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

318

The Affiliated Hospital of Xuzhou Medical College

Xuzhou · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

319

Zigong First People's Hospital

Zigong · China

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

320

Kardiologická ambulance Brno

Brno · Czechia

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

321

Angiocentrum Komorany

Prague · Czechia

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

322

Poliklinika Lípa Centrum

Prague · Czechia

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

323

Cardio Research, s.r.o

Zlín · Czechia

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

324

Sanos Clinic - Nordjylland

Gandrup · Denmark

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

325

Sanos Clinic

Herlev · Denmark

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

326

Sanos Clinic - Syddanmark

Vejle · Denmark

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

327

Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand

Dijon · France

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

328

Hopital Claude Huriez - CHU de Lille

Lille · France

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

329

Centre Hospitalier Saint Joseph - Saint Luc

Lyon · France

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

330

Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes

Nantes · France

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

331

Centre Hospitalier Universitaire de Nice - Hopital Pasteur

Nice · France

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

332

Pitie Salpetriere University Hospital

Paris · France

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

333

Hôpital Européen Georges Pompidou

Paris · France

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

334

Hôpital Bichat - Claude-Bernard

Paris · France

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

335

Hôpital Saint Antoine

Paris · France

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

336

CHU Strasbourg-Hautepierre

Strasbourg · France

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

337

CHU Rangueil

Toulouse · France

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

338

Universitätsklinikum Aachen

Aachen · Germany

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

339

Zentrum für klinische Studien Bad Homburg

Bad Homburg · Germany

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

340

Kardiologische Praxen im Spreebogen

Berlin · Germany

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

341

Charité Campus Virchow-Klinikum

Berlin · Germany

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

342

Hausärztlich-Kardiologisches MVZ am Felsenkeller GmbH/Zentrum für klinische Studien

Dresden · Germany

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

343

Herzzentrum Dresden GmbH Universitätsklinik

Dresden · Germany

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

344

Universitaetsklinikum Carl Gustav Carus Dresden

Dresden · Germany

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

345

Cardioangiologisches Centrum Bethanien

Frankfurt · Germany

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

346

Cardiologicum Hamburg

Hamburg · Germany

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

347

Universitaetsklinikum Heidelberg

Heidelberg · Germany

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

348

Universitätsklinikum Leipzig

Leipzig · Germany

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

349

Herzzentrum Leipzig GmbH

Leipzig · Germany

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

350

Praxis Oedeme

Lüneburg · Germany

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

351

Otto-von-Guericke-Universität Magdeburg

Magdeburg · Germany

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

352

ze:ro ARZTPRAXEN

Mannheim · Germany

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

353

Deutsches Herzzentrum München

Munich · Germany

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

354

Institut für Diabetesforschung GmbH Münster

Münster · Germany

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

355

Universitätsklinikum Regensburg

Regensburg · Germany

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

356

Studienzentrum Herzklinik Ulm MVZ

Ulm · Germany

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

357

University General Hospital of Heraklion

Heraklion · Greece

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

358

University Hospital of Ioannina

Ioannina · Greece

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

359

AHEPA University General Hospital of Thessaloniki

Thessaloniki · Greece

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

360

Medifarma 98 Kft

Nyíregyháza · Hungary

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

361

Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ

Szeged · Hungary

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

362

Vita Verum Medical Egeszsegugyi Szolgaltato

Székesfehérvár · Hungary

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

363

KLES Dr. Prabhakar Kore Hospital & M.R.C

Belagavi · India

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

364

K care Hospital

Kanpur · India

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

365

Government Medical College - Kozhikode

Kozhikode · India

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

366

King George's Medical University

Lucknow · India

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

367

Vijan Hospital & Research Centre

Nashik · India

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

368

G.B. Pant Institute of Postgraduate Medical Education & Research

New Delhi · India

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

369

All India Institute of Medical Sciences

Raipur · India

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

370

Ospedale Cazzavillan di Arzignano

Arzignano · Italy

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

371

Ospedale di Baggiovara

Baggiovara · Italy

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

372

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola

Bologna · Italy

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

373

Azienda Ospedaliero Universitaria S.Anna

Ferrara · Italy

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

374

Azienda Ospedaliera Universitaria Careggi

Florence · Italy

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

375

Ospedale San Martino

Genova · Italy

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

376

Centro Cardiologico Monzino

Milan · Italy

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

377

ASST Grande Ospedale Metropolitano Niguarda

Milan · Italy

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

378

Ospedale San Raffaele

Milan · Italy

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

379

Azienda Ospedale - Università Padova

Padova · Italy

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

380

Hospital Santa Maria della Misericordia in Perugia

Perugia · Italy

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

381

Fondazione G. Monasterio

Pisa · Italy

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

382

The Institute of Medical Science, Asahi Life Foundation

Chūōku · Japan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

383

Hakodate Municipal Hospital

Hakodate · Japan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

384

Tenyoukai Central Clinic

Kagoshima · Japan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

385

Kanazawa University Hospital

Kanazawa · Japan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

386

Miyazaki Medical Association Hospital

Miyazaki · Japan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

387

Iwate Prefectural Central Hospital

Morioka · Japan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

388

Nagoya City University Hospital

Nagoya · Japan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

389

Osaka Keisatsu Hospital

Osaka · Japan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

390

Osaka General Medical Center

Osaka · Japan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

391

Sapporo Medical University Hospital

Sapporo · Japan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

392

Japan Community Healthcare Organization Hokkaido Hospital

Sapporo · Japan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

393

Tokuyama Central Hospital

Shūnan · Japan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

394

National Cerebral and Cardiovascular Center

Suita · Japan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

395

Kagawa Prefectural Central Hospital

Takamatsu · Japan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

396

Osaka Medical and Pharmaceutical University Hospital

Takatsuki · Japan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

397

Sekino Hospital

Toshimaku · Japan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

398

Tsuchiura Kyodo General Hospital

Tsuchiura · Japan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

399

Fundación Cardiovascular de Aguascalientes A.C.

Aguascalientes · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

400

Instituto de Diabetes, Obesidad y Nutricion

Cuernavaca · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

401

Centro Para El Desarrollo de La Medicina Y de Asistencia Medica Especializada S.C.

Culiacán · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

402

Instituto Jalisciense de Investigacion en Diabetes y Obesidad

Guadalajara · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

403

Unidad de Investigación Clínica y Atención Médica HEPA S.C.

Guadalajara · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

404

Virgen Cardiovascular Research SC

Guadalajara · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

405

Instituto Cardiovascular de León S.C.

León · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

406

Grupo Medico Camino Sc

Mexico City · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

407

Hospital de Jésus, I.A.P.

Mexico City · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

408

Centro Médico Nacional Siglo XXI

Mexico City · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

409

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Mexico City · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

410

Medical Care and Research SA de CV

Mérida · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

411

Accelerium Clinical Research

Monterrey · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

412

Cardiolink Clin Trials

Monterrey · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

413

UBAM Unidad Biomedica Avanzada Monterrey

Monterrey · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

414

Clínica García Flores SC

Monterrey · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

415

Centro de investigación y control metabólico

Monterrey · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

416

Centro de Atención e Investigación Cardiovascular del Potosí

San Luis Potosí City · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

417

Servicios Integrales Nova de Monterrey S.A. de C.V.

San Nicolás de los Garza · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

418

Medimanage Research

Tlalpan · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

419

Hospital Angeles Xalapa

Xalapa · Mexico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

420

Meander Medisch Centrum

Amersfoort · Netherlands

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

421

Amsterdam UMC, locatie AMC

Amsterdam · Netherlands

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

422

Ziekenhuis Gelderse Vallei

Ede · Netherlands

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

423

Tergooiziekenhuizen, locatie Hilversum

Hilversum · Netherlands

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

424

Leids Universitair Medisch Centrum

Leiden · Netherlands

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

425

Bravis Ziekenhuis, locatie Roosendaal

Roosendaal · Netherlands

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

426

Erasmus Medisch Centrum

Rotterdam · Netherlands

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

427

Universitair Medisch Centrum Utrecht

Utrecht · Netherlands

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

428

NZOZ Twoje Zdrowie EL Sp. z o. o.

Elblag · Poland

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

429

NZOZ Salvia CM

Katowice · Poland

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

430

Centrum Medyczne Linden

Krakow · Poland

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

431

Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczne DIAB-ENDO-MET

Krakow · Poland

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

432

Poliklinika Kardiologiczna Serce

Leszno · Poland

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

433

Centra Medyczne Medyceusz

Lodz · Poland

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

434

Instytut Centrum Zdrowia Matki Polki

Lodz · Poland

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

435

Clinical Best Solutions

Lublin · Poland

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

436

Private Practice - Dr. Michał Tomaszewski

Lublin · Poland

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

437

Centrum Szybkiej Diagnostyki Kardiologicznej "Kardiomed" M. Żabówka E. Żabówka

Tarnów · Poland

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

438

4 Wojskowy Szpital Kliniczny z Polikliniką SPZOZ

Wroclaw · Poland

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

439

Advanced Clinical Research, LLC

Bayamón · Puerto Rico

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

440

Nicodiab

Bucharest · Romania

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

441

Hightech Medical Services SRL-Centrul pentru Studiul Metabolismului

Bucharest · Romania

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

442

Centrul Medical NutriLife

Bucharest · Romania

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

443

Spitalul Universitar de Urgență București

Bucharest · Romania

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

444

Mat Cord Biomedica S.R.L.

Buzău · Romania

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

445

Diamed Obesity

Galați · Romania

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

446

Clinica Korall

Satu Mare · Romania

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

447

Gensan S.R.L. - Policlinica Astra Sibiu

Sibiu · Romania

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

448

SC Dentosim Queen SRL - Centrul Medical Diamed

Târgu Mureş · Romania

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

449

Centrul Medical Mediab

Târgu Mureş · Romania

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

450

Mediab S.R.L.

Târgu Mureş · Romania

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

451

Private Practice - Dr. Cristian Podoleanu

Târgu Mureş · Romania

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

452

Cabinet Medical Dr.Geru

Timișoara · Romania

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

453

Institutul de Boli Cardiovasculare Timișoara

Timișoara · Romania

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

454

Daegu Catholic University Medical Center

Daegu · South Korea

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

455

Gachon University Gil Medical Center

Namdong-gu · South Korea

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

456

Seoul National University Bundang Hospital

Seongnam · South Korea

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

457

Korea University Anam Hospital

Seoul · South Korea

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

458

Kangbuk Samsung Hospital

Seoul · South Korea

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

459

Severance Hospital, Yonsei University Health System

Seoul · South Korea

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

460

Asan Medical Center

Seoul · South Korea

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

461

The Catholic Univ. of Korea Seoul St. Mary's Hospital

Seoul · South Korea

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

462

Korea University Guro Hospital

Seoul · South Korea

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

463

The Catholic University Of Korea St. Vincent's Hospital

Suwon · South Korea

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

464

Ulsan University Hospital

Ulsan · South Korea

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

465

Hospital Clínic de Barcelona

Barcelona · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

466

Complejo Hospitalario Universitario de Ferrol (CHUF)- Hospital Naval

Ferrol · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

467

Hospital Universitario Virgen Nieves

Granada · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

468

Hospital Infanta Elena

Huelva · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

469

Hospital Universitario de Jaen

Jaén · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

470

Hospital Universitari de Bellvitge

L'Hospitalet de Llobregat · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

471

FutureMeds - Madrid

Madrid · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

472

Hospital Universitario 12 de Octubre

Madrid · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

473

Hospital Universitario Virgen de la Victoria

Málaga · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

474

Hospital Universitari Son Espases

Palma · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

475

Salut Sant Joan de Reus-Baix Camp (Edp)

Reus · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

476

Hospital Virgen del Camino

Sanlúcar de Barrameda · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

477

Hospital Universitario Marqués de Valdecilla

Santander · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

478

CHUS - Hospital Clinico Universitario

Santiago de Compostela · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

479

Hospital General de Segovia

Segovia · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

480

FutureMeds - Sevilla

Seville · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

481

Vithas Hospital Sevilla

Seville · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

482

Hospital Clinico de Valencia

Valencia · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

483

Hospital Virgen de las Montañas

Villamartín · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

484

Hospital Universitario Miguel Servet

Zaragoza · Spain

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

485

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City · Taiwan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

486

Chang Gung Memorial Hospital at Kaohsiung

Kaohsiung Niao Sung Dist · Taiwan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

487

Chi Mei Medical Center

Tainan · Taiwan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

488

National Taiwan University Hospital

Taipei · Taiwan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

489

Cathay General Hospital

Taipei · Taiwan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

490

Taipei Medical University Hospital

Taipei · Taiwan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

491

Shin Kong Wu Ho-Su Memorial Hospital

Taipei · Taiwan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

492

Taipei Veterans General Hospital

Taipei · Taiwan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

493

Tri-Service General Hospital

Taipei · Taiwan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

494

Chang Gung Medical Foundation-Linkou Branch

Taoyuan · Taiwan

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

495

Layton Medical Centre

Blackpool · United Kingdom

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

496

Panthera Biopartners - North London

Enfield · United Kingdom

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

497

Panthera Biopartners - Preston

Preston · United Kingdom

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

498

Panthera Biopartners - Manchester

Rochdale · United Kingdom

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

499

Panthera Biopartners - Sheffield

Sheffield · United Kingdom

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

500

Sandwell General Hospital

West Bromwich · United Kingdom

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

501

Panthera Clinic - York

York · United Kingdom

2 trials

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

502

Centennial Medical Group

Columbia · Maryland · United States

2 trials

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

503

Medical University of South Carolina

Charleston · South Carolina · United States

2 trials

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

504

Clinitrials - Mandurah

Greenfields · Australia

2 trials

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

505

Research Site

Garden Grove · California · United States

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

506

Research Site

San Diego · California · United States

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

507

Research Site

Orlando · Florida · United States

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

508

Research Site

Peachtree Corners · Georgia · United States

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

509

Research Site

Chicago · Illinois · United States

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

510

Research Site

Hammond · Louisiana · United States

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

511

Research Site

Morganton · North Carolina · United States

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

512

Research Site

Lima · Ohio · United States

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

513

Research Site

Houston · Texas · United States

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

514

Research Site

Humble · Texas · United States

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

515

Research Site

Mesquite · Texas · United States

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

516

Research Site

Redmond · Washington · United States

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

517

Research Site

CABA · Argentina

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

518

Research Site

Ciudad Autonoma de Bs As · Argentina

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

519

Research Site

Ciudad de Buenos Aires · Argentina

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

520

Research Site

Mar del Plata · Argentina

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

521

Research Site

Rosario · Argentina

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

522

Research Site

Melbourne · Australia

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

523

Research Site

Campinas · Brazil

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

524

Research Site

São Paulo · Brazil

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

525

Research Site

Plovdiv · Bulgaria

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

526

Research Site

Sofia · Bulgaria

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

527

Research Site

Vancouver · British Columbia · Canada

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

528

Research Site

Chicoutimi · Quebec · Canada

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

529

Research Site

Montreal · Quebec · Canada

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

530

Research Site

Québec · Quebec · Canada

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

531

Research Site

Santiago · Chile

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

532

Research Site

Valdivia · Chile

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

533

Research Site

Prague · Czechia

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

534

Research Site

Uherské Hradiště · Czechia

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

535

Research Site

Berlin · Germany

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

536

Research Site

Dresden · Germany

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

537

Research Site

Leipzig · Germany

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

538

Research Site

Budapest · Hungary

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

539

Research Site

Debrecen · Hungary

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

540

Research Site

Nyíregyháza · Hungary

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

541

Research Site

Székesfehérvár · Hungary

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

542

Research Site

Chūōku · Japan

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

543

Research Site

Hamamatsu · Japan

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

544

Research Site

Ichikawa-shi · Japan

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

545

Research Site

Kanazawa · Japan

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

546

Research Site

Kishiwada-shi · Japan

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

547

Research Site

Komatsu-shi · Japan

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

548

Research Site

Minatoku · Japan

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

549

Research Site

Okayama · Japan

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

550

Research Site

Osaka · Japan

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

551

Research Site

Tamanashi · Japan

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

552

Research Site

Urasoe-Shi · Japan

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

553

Research Site

Yokohama · Japan

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

554

Research Site

Bratislava · Slovakia

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

555

Research Site

Košice · Slovakia

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

556

Research Site

Seoul · South Korea

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

557

Research Site

A Coruña · Spain

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

558

Research Site

Barcelona · Spain

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

559

Research Site

Córdoba · Spain

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

560

Research Site

Seville · Spain

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

561

Research Site

Kaohsiung City · Taiwan

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

562

Research Site

Taichung · Taiwan

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

563

Research Site

Taipei · Taiwan

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

564

Research Site

Adana · Turkey (Türkiye)

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

565

Research Site

Afyonkarahisar · Turkey (Türkiye)

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

566

Research Site

Ankara · Turkey (Türkiye)

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

567

Research Site

Izmir · Turkey (Türkiye)

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

568

Research Site

Hanoi · Vietnam

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

569

Research Site

Ho Chi Minh City · Vietnam

2 trials

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

570

Research Site

Inverness · Florida · United States

2 trials

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

AZD4954 treats elevated lipoprotein(a) and abnormal cholesterol levels in healthy and dyslipidemic adults.

AstraZenecaPh 1RecruitingNCT06980428 ↗

571

Research Site

Jacksonville · Florida · United States

2 trials

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

AZD4954 treats elevated lipoprotein(a) and abnormal cholesterol levels in healthy and dyslipidemic adults.

AstraZenecaPh 1RecruitingNCT06980428 ↗

572

Research Site

San Antonio · Texas · United States

2 trials

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

AZD4954 treats elevated lipoprotein(a) and abnormal cholesterol levels in healthy and dyslipidemic adults.

AstraZenecaPh 1RecruitingNCT06980428 ↗

573

Ocala Cardiovascular Research

Ocala · Florida · United States

2 trials

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

574

Nanfang Hospital, Southern Medical University

Guangzhou · Guangdong · China

1 trial

SAL0167 drug safety and dose effects evaluated in healthy volunteers.

Shenzhen Salubris Pharmaceuticals Co., Ltd.Ph 1NCT07722299 ↗

575

Hopitaux Universitaires de Genève

Geneva · Switzerland

1 trial

Study examines how blood platelets behave in people with high lipoprotein(a) and tests antiplatelet medications.

François MACHNCT07720934 ↗

576

Research Site

Aramil · Russia

1 trial

AZD0780 combined with rosuvastatin lowers LDL cholesterol more than placebo in Russian adults with high cholesterol.

AstraZenecaPh 2NCT07218900 ↗

577

Research Site

Ivanovo · Russia

1 trial

AZD0780 combined with rosuvastatin lowers LDL cholesterol more than placebo in Russian adults with high cholesterol.

AstraZenecaPh 2NCT07218900 ↗

578

Research Site

Moscow · Russia

1 trial

AZD0780 combined with rosuvastatin lowers LDL cholesterol more than placebo in Russian adults with high cholesterol.

AstraZenecaPh 2NCT07218900 ↗

579

Research Site

Perm · Russia

1 trial

AZD0780 combined with rosuvastatin lowers LDL cholesterol more than placebo in Russian adults with high cholesterol.

AstraZenecaPh 2NCT07218900 ↗

580

Research Site

Saint Petersburg · Russia

1 trial

AZD0780 combined with rosuvastatin lowers LDL cholesterol more than placebo in Russian adults with high cholesterol.

AstraZenecaPh 2NCT07218900 ↗

581

"Attikon" University General Hospital

Athens · Attica · Greece

1 trial

Study investigates how elevated lipoprotein(a) affects blood vessel stiffness and heart function in affected patients.

University of AthensRecruitingNCT07324902 ↗

582

Attikon University Hospital, 2nd Department of Cardiology, National and Kapodistrina University of Athens

Athens · Rimini 1 · Greece

1 trial

Study investigates how elevated lipoprotein(a) affects blood vessel stiffness and heart function in affected patients.

University of AthensRecruitingNCT07324902 ↗

583

Chu de Nice

Nice · France · France

1 trial

Research examines elevated lipoprotein(a) levels in lymphedema patients as potential cardiovascular risk factor.

Centre Hospitalier Universitaire de NiceRecruitingNCT05962827 ↗

584

Centre antoine lacassagne

Nice · France · France

1 trial

Research examines elevated lipoprotein(a) levels in lymphedema patients as potential cardiovascular risk factor.

Centre Hospitalier Universitaire de NiceTERMINATEDNCT05962827 ↗

585

SEC Clinical Research LLC

Andalusia · Alabama · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

586

Cardiology and Medicine Clinic PA

Little Rock · Arkansas · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

587

Cardiovascular Res Found

Beverly Hills · California · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

588

Valley Clinical Trials Inc

Covina · California · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

589

Diabetes Lipid Management Center

Huntington Beach · California · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

590

University of Calif Irvine Med Cntr

Irvine · California · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

591

Memorial Care Health System

Long Beach · California · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

592

Keck Medical Center USC

Los Angeles · California · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

593

Stanford University Medical Center

Palo Alto · California · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

594

University of California San Diego

San Diego · California · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

595

UCSF

San Francisco · California · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

596

Helping Hands Medical Associates INC

Santa Ana · California · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

597

Univ Of Color Anschutz Med Center

Aurora · Colorado · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

598

Hartford Hospital

Hartford · Connecticut · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

599

Bay Area Cardiology Assoc

Brandon · Florida · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

600

Advanced Research for Health Improvement LLC

Naples · Florida · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

601

East Coast Inst for Research LLC

Saint Augustine · Florida · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

602

Cardiology Partners Clinical Research Institute

Wellington · Florida · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

603

Piedmont Heart Institute

Atlanta · Georgia · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

604

Emory University

Atlanta · Georgia · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

605

Cardiovascular Consultants of S GA

Thomasville · Georgia · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

606

Rush University Medical Center

Chicago · Illinois · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

607

Krannert Institute of Cardiology

Indianapolis · Indiana · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

608

Uni Of Iowa Hospitals And Clinics

Iowa City · Iowa · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

609

University of Kansas Hospital

Kansas City · Kansas · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

610

Cotton O Neil Clinical Res Center

Topeka · Kansas · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

611

Louisiana Heart Center Research

Bogalusa · Louisiana · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

612

Louisiana Heart Center Research

Covington · Louisiana · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

613

CV Institute of the South

Houma · Louisiana · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

614

Horizon Research Grp

Lafayette · Louisiana · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

615

Tulane Center for Clinical Research

New Orleans · Louisiana · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

616

CV Ins of the South

Opelousas · Louisiana · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

617

Grace Research Llc

Shreveport · Louisiana · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

618

Louisiana Heart Center Research

Slidell · Louisiana · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

619

Southern Clinical Research

Zachary · Louisiana · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

620

Maine Health Cardiology

Scarborough · Maine · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

621

Sinai Ct for Throm Res and Drug Dev

Baltimore · Maryland · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

622

Johns Hopkins Univ School of Med

Baltimore · Maryland · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

623

Adventist HealthCare Shady Grove Medical Center

Rockville · Maryland · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

624

MGH

Boston · Massachusetts · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

625

Brigham and Womens Hosp Harvard Med School

Boston · Massachusetts · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

626

Wayne State University

Detroit · Michigan · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

627

AA Medical Research Center

Flint · Michigan · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

628

Western Michigan University

Kalamazoo · Michigan · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

629

McLaren Ctr Research Innovation

Petoskey · Michigan · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

630

Central Michigan University

Saginaw · Michigan · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

631

Metro Health Univ of MI Health

Wyoming · Michigan · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

632

Saint Johns Hospital

Maplewood · Minnesota · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

633

Minneapolis Heart Institute

Minneapolis · Minnesota · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

634

Belzoni Clinical Research

Belzoni · Mississippi · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

635

Stern Cardiovascular Foundation Inc

Southaven · Mississippi · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

636

Mercy Hospital St Louis

St Louis · Missouri · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

637

Quality Clinical Research

Omaha · Nebraska · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

638

Dartmouth Hitchcock Medical Center

Lebanon · New Hampshire · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

639

The Valley Hospital

Ridgewood · New Jersey · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

640

Northwell Health

Manhasset · New York · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

641

Weill Cornell Medical Center

New York · New York · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

642

Icahn School of Med at Mt Sinai

New York · New York · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

643

Novant Health Heart Vas Inst

Charlotte · North Carolina · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

644

Accellacare US Inc

Raleigh · North Carolina · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

645

Akron Hospital Summa Health System

Akron · Ohio · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

646

Aultman Hospital

Canton · Ohio · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

647

Lindner Ctr At The Christ Hosp

Cincinnati · Ohio · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

648

Cleveland Clinic Foundation

Cleveland · Ohio · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

649

Rama Research LLC

Marion · Ohio · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

650

Lancaster General Health

Lancaster · Pennsylvania · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

651

Perelman School of Medicine

Philadelphia · Pennsylvania · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

652

Allegheny General Hospital

Pittsburgh · Pennsylvania · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

653

Cardiology Consultants of Philadelphia

Yardley · Pennsylvania · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

654

The Stern Cardiovascular Foundation

Germantown · Tennessee · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

655

Apex Cardiology Research Associates of Jackson

Jackson · Tennessee · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

656

Vanderbilt Univ Medi Cen

Nashville · Tennessee · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

657

Cardiovascular Res of Knoxville LLC

Powell · Tennessee · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

658

Soltero Cardiovascular Research Center

Dallas · Texas · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

659

North Texas Endocrine Center

Dallas · Texas · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

660

SW Family Medicine Associates

Dallas · Texas · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

661

Grace Research

Marshall · Texas · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

662

Progressive Clinical Research

Bountiful · Utah · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

663

The University of Utah

Salt Lake City · Utah · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

664

Inova Fairfax Hospital

Falls Church · Virginia · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

665

Dominion Medical Associates

Richmond · Virginia · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

666

Harborview Medical Center

Seattle · Washington · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

667

Swedish Medical Center-Cardiovascular Research

Seattle · Washington · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

668

Univ of Washington Medical Center

Seattle · Washington · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

669

West Virginia University Hospital

Morgantown · West Virginia · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

670

St Luke s Medical Center Aurora

Milwaukee · Wisconsin · United States

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

671

Novartis Investigative Site

Caba · Argentina

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

672

Novartis Investigative Site

Mar del Plata · Buenos Aires · Argentina

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

673

Novartis Investigative Site

Ramos Mejía · Buenos Aires · Argentina

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

674

Novartis Investigative Site

Córdoba · Argentina

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

675

Novartis Investigative Site

San Miguel de Tucumán · San Miguel de Tucuman · Argentina

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

676

Novartis Investigative Site

Rosario · Santa Fe Province · Argentina

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

677

Novartis Investigative Site

Santa Fe · Santa Fe Province · Argentina

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

678

Novartis Investigative Site

Buenos Aires · Argentina

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

679

Novartis Investigative Site

Capital Federal · Argentina

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

680

Novartis Investigative Site

Corrientes · Argentina

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

681

Novartis Investigative Site

San Luis · Argentina

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

682

Novartis Investigative Site

Camperdown · New South Wales · Australia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

683

Novartis Investigative Site

Liverpool · New South Wales · Australia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

684

Novartis Investigative Site

Chemside · Queensland · Australia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

685

Novartis Investigative Site

Woolloongabba · Queensland · Australia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

686

Novartis Investigative Site

Clayton · Victoria · Australia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

687

Novartis Investigative Site

Perth · Western Australia · Australia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

688

Novartis Investigative Site

Graz · Austria

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

689

Novartis Investigative Site

Innsbruck · Austria

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

690

Novartis Investigative Site

Linz · Austria

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

691

Novartis Investigative Site

Salzburg · Austria

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

692

Novartis Investigative Site

Brussels · Brussels Capital · Belgium

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

693

Novartis Investigative Site

Genk · Limburg · Belgium

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

694

Novartis Investigative Site

Aalst · Oost Vlaanderen · Belgium

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

695

Novartis Investigative Site

Kortrijk · West-Vlaanderen · Belgium

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

696

Novartis Investigative Site

Bruges · Belgium

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

697

Novartis Investigative Site

Dendermonde · Belgium

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

698

Novartis Investigative Site

Huy · Belgium

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

699

Novartis Investigative Site

Mechelen · Belgium

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

700

Novartis Investigative Site

Vitória · Espírito Santo · Brazil

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

701

Novartis Investigative Site

Salvador · Estado de Bahia · Brazil

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

702

Novartis Investigative Site

Goiânia · Goiás · Brazil

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

703

Novartis Investigative Site

Belo Horizonte · Minas Gerais · Brazil

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

704

Novartis Investigative Site

Juiz de Fora · Minas Gerais · Brazil

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

705

Novartis Investigative Site

Uberlândia · Minas Gerais · Brazil

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

706

Novartis Investigative Site

Curitiba · Paraná · Brazil

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

707

Novartis Investigative Site

Canoas · Rio Grande do Sul · Brazil

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

708

Novartis Investigative Site

Porto Alegre · Rio Grande do Sul · Brazil

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

709

Novartis Investigative Site

Blumenau · Santa Catarina · Brazil

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

710

Novartis Investigative Site

Aracaju · Sergipe · Brazil

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

711

Novartis Investigative Site

Campinas · São Paulo · Brazil

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

712

Novartis Investigative Site

Ribeirão Preto · São Paulo · Brazil

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

713

Novartis Investigative Site

Santo André · São Paulo · Brazil

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

714

Novartis Investigative Site

Sao Jose Rio Preto · São Paulo · Brazil

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

715

Novartis Investigative Site

São Paulo · São Paulo · Brazil

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

716

Novartis Investigative Site

Rio de Janeiro · Brazil

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

717

Novartis Investigative Site

Burgas · Bulgaria

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

718

Novartis Investigative Site

Pernik · Bulgaria

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

719

Novartis Investigative Site

Pleven · Bulgaria

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

720

Novartis Investigative Site

Plovdiv · Bulgaria

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

721

Novartis Investigative Site

Rousse · Bulgaria

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

722

Novartis Investigative Site

Sofia · Bulgaria

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

723

Novartis Investigative Site

Vancouver · British Columbia · Canada

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

724

Novartis Investigative Site

Victoria · British Columbia · Canada

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

725

Novartis Investigative Site

Oakville · Ontario · Canada

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

726

Novartis Investigative Site

Toronto · Ontario · Canada

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

727

Novartis Investigative Site

Lévis · Quebec · Canada

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

728

Novartis Investigative Site

Montreal · Quebec · Canada

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

729

Novartis Investigative Site

Québec · Quebec · Canada

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

730

Novartis Investigative Site

Foshan · Guangdong · China

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

731

Novartis Investigative Site

Changsha · Hunan · China

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

732

Novartis Investigative Site

Baotou · Inner Mongolia · China

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

733

Novartis Investigative Site

Nanjing · Jiangsu · China

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

734

Novartis Investigative Site

Suzhou · Jiangsu · China

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

735

Novartis Investigative Site

Xuzhou · Jiangsu · China

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

736

Novartis Investigative Site

Shenyang · Liaoning · China

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

737

Novartis Investigative Site

Jinan · Shandong · China

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

738

Novartis Investigative Site

Ürümqi · Xinjiang · China

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

739

Novartis Investigative Site

Hangzhou · Zhejiang · China

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

740

Novartis Investigative Site

Xiamen · China

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

741

Novartis Investigative Site

Medellín · Colombia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

742

Novartis Investigative Site

Barranquilla · Colombia · Colombia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

743

Novartis Investigative Site

Bucaramanga · Santander Department · Colombia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

744

Novartis Investigative Site

Cali · Valle del Cauca Department · Colombia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

745

Novartis Investigative Site

Bogotá · Colombia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

746

Novartis Investigative Site

San Gil · Colombia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

747

Novartis Investigative Site

Kroměříž · Czech Republic · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

748

Novartis Investigative Site

Louny · Czech Republic · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

749

Novartis Investigative Site

Ostrava · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

750

Novartis Investigative Site

Ústí nad Labem · Czech Republic · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

751

Novartis Investigative Site

Brandýs nad Labem · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

752

Novartis Investigative Site

Brno · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

753

Novartis Investigative Site

Broumov · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

754

Novartis Investigative Site

Chlumec nad Cidlinou · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

755

Novartis Investigative Site

CZE · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

756

Novartis Investigative Site

Český Krumlov · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

757

Novartis Investigative Site

Hlučín · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

758

Novartis Investigative Site

Hodonín · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

759

Novartis Investigative Site

Jihlava · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

760

Novartis Investigative Site

Kolín · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

761

Novartis Investigative Site

Liberec · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

762

Novartis Investigative Site

Mariánské Lázně · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

763

Novartis Investigative Site

Mělník · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

764

Novartis Investigative Site

Most · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

765

Novartis Investigative Site

Olomouc · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

766

Novartis Investigative Site

Pardubice · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

767

Novartis Investigative Site

Polička · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

768

Novartis Investigative Site

Prague · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

769

Novartis Investigative Site

Přerov · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3WITHDRAWNNCT07517263 ↗

770

Novartis Investigative Site

Slaný · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

771

Novartis Investigative Site

Trutnov · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

772

Novartis Investigative Site

Třebíč · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

773

Novartis Investigative Site

Uherské Hradiště · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

774

Novartis Investigative Site

Valašské Meziříčí · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

775

Novartis Investigative Site

Zlín · Czechia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

776

Novartis Investigative Site

Aarhus N · Denmark

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

777

Novartis Investigative Site

Copenhagen · Denmark

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

778

Novartis Investigative Site

Esbjerg · Denmark

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

779

Novartis Investigative Site

Gistrup · Denmark

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

780

Novartis Investigative Site

Herlev · Denmark

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

781

Novartis Investigative Site

Roskilde · Denmark

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

782

Novartis Investigative Site

Viborg · Denmark

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

783

Novartis Investigative Site

Bron · France

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

784

Novartis Investigative Site

Chambray-lès-Tours · France

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

785

Novartis Investigative Site

Compiègne · France

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

786

Novartis Investigative Site

Le Coudray · France

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

787

Novartis Investigative Site

Nantes · France

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

788

Novartis Investigative Site

Valenciennes · France

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

789

Novartis Investigative Site

Muehldorf Am Inn · Bavaria · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

790

Novartis Investigative Site

Munich · Bavaria · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

791

Novartis Investigative Site

Weiden in Der Oberpfalz · Bavaria · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

792

Novartis Investigative Site

Hanover · Lower Saxony · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

793

Novartis Investigative Site

Cologne · North Rhine-Westphalia · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

794

Novartis Investigative Site

Essen · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

795

Novartis Investigative Site

Löhne · North Rhine-Westphalia · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

796

Novartis Investigative Site

Saint Ingbert · Saarland · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

797

Novartis Investigative Site

Dresden · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

798

Novartis Investigative Site

Wittenberg · Saxony-Anhalt · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

799

Novartis Investigative Site

Jena · Thuringia · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

800

Novartis Investigative Site

Aachen · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

801

Novartis Investigative Site

Bad Homburg · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

802

Novartis Investigative Site

Bad Krozingen · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

803

Novartis Investigative Site

Bad Oeynhausen · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

804

Novartis Investigative Site

Bamberg · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

805

Novartis Investigative Site

Dessau · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

806

Novartis Investigative Site

Dortmund · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

807

Novartis Investigative Site

Hamburg · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

808

Novartis Investigative Site

Kassel · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

809

Novartis Investigative Site

Lüneburg · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

810

Novartis Investigative Site

Magdeburg · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

811

Novartis Investigative Site

Meissen · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

812

Novartis Investigative Site

München · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

813

Novartis Investigative Site

Rüdersdorf · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

814

Novartis Investigative Site

Ulm · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

815

Novartis Investigative Site

Warendorf · Germany

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

816

Novartis Investigative Site

Athens · Greece

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

817

Novartis Investigative Site

Larissa · Greece

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

818

Novartis Investigative Site

Debrecen · Hajdu Bihar Megye · Hungary

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

819

Novartis Investigative Site

Baja · Hungary

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

820

Novartis Investigative Site

Budapest · Hungary

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

821

Novartis Investigative Site

Szeged · Hungary

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

822

Novartis Investigative Site

Reykjavik · Iceland

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

823

Novartis Investigative Site

Guntur · Andhra Pradesh · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

824

Novartis Investigative Site

Ahmedabad · Gujarat · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

825

Novartis Investigative Site

Vadodara · Gujarat · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

826

Novartis Investigative Site

Belagavi · Karnataka · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

827

Novartis Investigative Site

Mangalore · Karnataka · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

828

Novartis Investigative Site

Manipal · Karnataka · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

829

Novartis Investigative Site

Kochi · Kerala · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

830

Novartis Investigative Site

Nagpur · Maharashtra · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

831

Novartis Investigative Site

Nashik · Maharashtra · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

832

Novartis Investigative Site

Pune · Maharashtra · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

833

Novartis Investigative Site

New Delhi · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

834

Novartis Investigative Site

Bikaner · Rajasthan · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

835

Novartis Investigative Site

Chennai · Tamil Nadu · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

836

Novartis Investigative Site

Coimbatore · Tamil Nadu · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

837

Novartis Investigative Site

Hyderabad · Telangana · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

838

Novartis Investigative Site

Secunderabad · Telangana · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

839

Novartis Investigative Site

Ghaziabad · Uttar Pradesh · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

840

Novartis Investigative Site

Lucknow · Uttar Pradesh · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

841

Novartis Investigative Site

Dehradun · Uttarakhand · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

842

Novartis Investigative Site

Mysore · India

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

843

Novartis Investigative Site

Beersheba · Israel

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

844

Novartis Investigative Site

Haifa · Israel

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

845

Novartis Investigative Site

Holon · Israel

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

846

Novartis Investigative Site

Jerusalem · Israel

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

847

Novartis Investigative Site

Petah Tikva · Israel

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

848

Novartis Investigative Site

Ramat Gan · Israel

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

849

Novartis Investigative Site

Bergamo · BG · Italy

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

850

Novartis Investigative Site

Bologna · BO · Italy

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

851

Novartis Investigative Site

Brescia · BS · Italy

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

852

Novartis Investigative Site

Cona · FE · Italy

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

853

Novartis Investigative Site

Florence · FI · Italy

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

854

Novartis Investigative Site

Pozzilli · IS · Italy

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

855

Novartis Investigative Site

Palermo · PA · Italy

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

856

Novartis Investigative Site

Pisa · PI · Italy

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

857

Novartis Investigative Site

Roma · RM · Italy

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

858

Novartis Investigative Site

Varese · VA · Italy

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

859

Novartis Investigative Site

Naples · Italy

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

860

Novartis Investigative Site

Nagoya · Aichi-ken · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

861

Novartis Investigative Site

Seto · Aichi-ken · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

862

Novartis Investigative Site

Hirosaki · Aomori · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

863

Novartis Investigative Site

Asahi · Chiba · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

864

Novartis Investigative Site

Funabashi · Chiba · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

865

Novartis Investigative Site

Matsudo · Chiba · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

866

Novartis Investigative Site

Kitakyushu · Fukuoka · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

867

Novartis Investigative Site

Ōgaki · Gifu · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

868

Novartis Investigative Site

Kure · Hiroshima · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

869

Novartis Investigative Site

Tsuchiura · Ibaraki · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

870

Novartis Investigative Site

Komatsu · Ishikawa-ken · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

871

Novartis Investigative Site

Takamatsu · Kagawa-ken · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

872

Novartis Investigative Site

Kawasaki · Kanagawa · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

873

Novartis Investigative Site

Sagamihara · Kanagawa · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

874

Novartis Investigative Site

Yokohama · Kanagawa · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

875

Novartis Investigative Site

Sendai · Miyagi · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

876

Novartis Investigative Site

Miyhazaki · Miyazaki · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

877

Novartis Investigative Site

Osaka · Osaka · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

878

Novartis Investigative Site

Sayama · Saitama · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

879

Novartis Investigative Site

Ōmihachiman · Shiga · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

880

Novartis Investigative Site

Bunkyo Ku · Tokyo · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

881

Novartis Investigative Site

Chuo Ku · Tokyo · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

882

Novartis Investigative Site

Chuo-ku · Tokyo · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

883

Novartis Investigative Site

Hachiōji · Tokyo · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

884

Novartis Investigative Site

Itabashi-ku · Tokyo · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

885

Novartis Investigative Site

Ōta-ku · Tokyo · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

886

Novartis Investigative Site

Ishikawa · Japan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

887

Novartis Investigative Site

Apeldoorn · Gelderland · Netherlands

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

888

Novartis Investigative Site

Arnhem · Gelderland · Netherlands

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

889

Novartis Investigative Site

Tiel · Gelderland · Netherlands

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

890

Novartis Investigative Site

Heerlen · Limburg · Netherlands

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

891

Novartis Investigative Site

Tilburg · North Brabant · Netherlands

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

892

Novartis Investigative Site

Alkmaar · North Holland · Netherlands

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

893

Novartis Investigative Site

Heemstede · North Holland · Netherlands

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

894

Novartis Investigative Site

Deventer · Overijssel · Netherlands

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

895

Novartis Investigative Site

Zwolle · Overijssel · Netherlands

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

896

Novartis Investigative Site

Sneek · Provincie Friesland · Netherlands

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

897

Novartis Investigative Site

Groningen · Provincie Groningen · Netherlands

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

898

Novartis Investigative Site

Leiden · South Holland · Netherlands

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

899

Novartis Investigative Site

Leiderdorp · South Holland · Netherlands

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

900

Novartis Investigative Site

Amersfoort · Netherlands

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

901

Novartis Investigative Site

Gouda · Netherlands

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

902

Novartis Investigative Site

Hardenberg · Netherlands

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

903

Novartis Investigative Site

Nijmegen · Netherlands

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

904

Novartis Investigative Site

Utrecht · Netherlands

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

905

Novartis Investigative Site

Venlo · Netherlands

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

906

Novartis Investigative Site

Oslo · Norway

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

907

Novartis Investigative Site

Skedsmokorset · Norway

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

908

Novartis Investigative Site

Bielsko-Biala · Poland

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

909

Novartis Investigative Site

Chrzanów · Poland

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

910

Novartis Investigative Site

Gdansk · Poland

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

911

Novartis Investigative Site

Gdynia · Poland

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

912

Novartis Investigative Site

Lodz · Poland

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

913

Novartis Investigative Site

Tarnów · Poland

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

914

Novartis Investigative Site

Coimbra · Portugal

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

915

Novartis Investigative Site

Guimarães · Portugal

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

916

Novartis Investigative Site

Setúbal · Portugal

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

917

Research and Cardiovascular Corp

Ponce · Puerto Rico

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

918

Novartis Investigative Site

Buzău · Buzău · Romania

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

919

Novartis Investigative Site

Craiova · Dolj · Romania

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

920

Novartis Investigative Site

Baia Mare · Maramureş · Romania

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

921

Novartis Investigative Site

Bucharest · Romania

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

922

Novartis Investigative Site

Saint Petersburg · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

923

Novartis Investigative Site

Chelyabinsk · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

924

Novartis Investigative Site

Ivanovo · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

925

Novartis Investigative Site

Izhevsk · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

926

Novartis Investigative Site

Kemerovo · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

927

Novartis Investigative Site

Kirov · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

928

Novartis Investigative Site

Krasnodar · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

929

Novartis Investigative Site

Moscow · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

930

Novartis Investigative Site

Novosibirsk · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

931

Novartis Investigative Site

Perm · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

932

Novartis Investigative Site

Rostov-on-Don · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

933

Novartis Investigative Site

Ryazan · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

934

Novartis Investigative Site

Samara · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

935

Novartis Investigative Site

Saratov · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

936

Novartis Investigative Site

Sochy · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

937

Novartis Investigative Site

Tomsk · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

938

Novartis Investigative Site

Ulyanovsk · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

939

Novartis Investigative Site

Vsevolozhsk · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

940

Novartis Investigative Site

Yaroslavl · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

941

Novartis Investigative Site

Yekaterinburg · Russia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

942

Novartis Investigative Site

Trnava · Slovakia · Slovakia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

943

Novartis Investigative Site

Bardejov · Slovakia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

944

Novartis Investigative Site

Bratislava · Slovakia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3WITHDRAWNNCT07517263 ↗

945

Novartis Investigative Site

Handlová · Slovakia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

946

Novartis Investigative Site

Komárno · Slovakia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

947

Novartis Investigative Site

Košice · Slovakia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

948

Novartis Investigative Site

Lučenec · Slovakia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

949

Novartis Investigative Site

Nitra · Slovakia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

950

Novartis Investigative Site

Nové Zámky · Slovakia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

951

Novartis Investigative Site

Piešťany · Slovakia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

952

Novartis Investigative Site

Považská Bystrica · Slovakia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

953

Novartis Investigative Site

Prešov · Slovakia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

954

Novartis Investigative Site

Rimavská Sobota · Slovakia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

955

Novartis Investigative Site

Svidník · Slovakia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

956

Novartis Investigative Site

Ljubljana · Slovenia

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

957

Novartis Investigative Site

Cape Town · South Africa

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

958

Novartis Investigative Site

George · Western Cape · South Africa

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

959

Novartis Investigative Site

Daegu · Dalseo gu · South Korea

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

960

Novartis Investigative Site

Wŏnju · Gangwon-do · South Korea

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

961

Novartis Investigative Site

Bundang Gu · Gyeonggi-do · South Korea

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

962

Novartis Investigative Site

Suwon · Gyeonggi-do · South Korea

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

963

Novartis Investigative Site

Incheon · Korea · South Korea

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

964

Novartis Investigative Site

Seoul · South Korea

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

965

Novartis Investigative Site

Busan · South Korea

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

966

Novartis Investigative Site

Gwangju · South Korea

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

967

Novartis Investigative Site

Seville · Spain

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

968

Novartis Investigative Site

Badalona · Barcelona · Spain

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

969

Novartis Investigative Site

L'Hospitalet de Llobregat · Barcelona · Spain

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

970

Novartis Investigative Site

Santander · Cantabria · Spain

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

971

Novartis Investigative Site

Cáceres · Extremadura · Spain

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

972

Novartis Investigative Site

Reus · Tarragona · Spain

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

973

Novartis Investigative Site

Madrid · Spain

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

974

Novartis Investigative Site

Málaga · Spain

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

975

Novartis Investigative Site

Zaragoza · Spain

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

976

Novartis Investigative Site

Gothenburg · Sweden

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

977

Novartis Investigative Site

Lund · Sweden

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

978

Novartis Investigative Site

Stockholm · Sweden

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

979

Novartis Investigative Site

Basel · Switzerland

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

980

Novartis Investigative Site

Bern · Switzerland

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

981

Novartis Investigative Site

Geneva · Switzerland

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

982

Novartis Investigative Site

Lausanne · Switzerland

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

983

Novartis Investigative Site

Liestal · Switzerland

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

984

Novartis Investigative Site

Zurich · Switzerland

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

985

Novartis Investigative Site

Hsinchu · Taiwan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

986

Novartis Investigative Site

Keelung · Taiwan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

987

Novartis Investigative Site

Taoyuan · Taiwan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

988

Novartis Investigative Site

Yilan · Taiwan

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

989

Novartis Investigative Site

Istanbul · Kadikoy · Turkey (Türkiye)

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

990

Novartis Investigative Site

Eskişehir · Odunpazari · Turkey (Türkiye)

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

991

Novartis Investigative Site

Samsun · Samsun · Turkey (Türkiye)

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

992

Novartis Investigative Site

Mersin · Yenisehir · Turkey (Türkiye)

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

993

Novartis Investigative Site

Dorchester · Dorset · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

994

Novartis Investigative Site

Preston · Lancashire · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

995

Novartis Investigative Site

Harrow · Middlesex · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

996

Novartis Investigative Site

Rochdale · North Manchester · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

997

Novartis Investigative Site

Portadown · Nothern Ireland · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

998

Novartis Investigative Site

Taunton · Somerset · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

999

Novartis Investigative Site

Chertsey · Surrey · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

1000

Novartis Investigative Site

Newcastle upon Tyne · Tyne and Wear · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

1001

Novartis Investigative Site

Sunderland · Tyne and Wear · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

1002

Novartis Investigative Site

Cardiff · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

1003

Novartis Investigative Site

Birmingham · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

1004

Novartis Investigative Site

Bristol · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

1005

Novartis Investigative Site

Chesterfield · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

1006

Novartis Investigative Site

Edinburgh · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

1007

Novartis Investigative Site

Glasgow · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

1008

Novartis Investigative Site

Leicester · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

1009

Novartis Investigative Site

Londonderry · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

1010

Novartis Investigative Site

Middlesbrough · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

1011

Novartis Investigative Site

Middlesex · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

1012

Novartis Investigative Site

Newport · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

1013

Novartis Investigative Site

Norwich · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

1014

Novartis Investigative Site

Plymouth · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

1015

Novartis Investigative Site

Rhyl · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

1016

Novartis Investigative Site

Sheffield · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

1017

Novartis Investigative Site

Swansea · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

1018

Novartis Investigative Site

Wiltshire · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗

1019

Novartis Investigative Site

Wrexham · United Kingdom

1 trial

Long-term safety study of pelacarsen drug in patients completing earlier cholesterol-reduction trial.

Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗

1020

Site Number - 1056

Huntsville · Alabama · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1021

Site Number - 1041

Mobile · Alabama · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1022

Site Number - 1017

Phoenix · Arizona · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1023

Site Number - 1025

Scottsdale · Arizona · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1024

Site Number - 1042

Tucson · Arizona · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1025

Site Number - 1010

Carlsbad · California · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1026

Site Number - 1028

Irvine · California · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1027

Site Number - 1023

Los Angeles · California · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1028

Site Number - 1029

Rancho Mirage · California · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1029

Site Number - 1004

San Francisco · California · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1030

Site Number - 1027

Fort Collins · Colorado · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1031

Site Number - 1001

New Haven · Connecticut · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1032

Site Number - 1024

Washington D.C. · District of Columbia · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1033

Site Number - 1006

Clearwater · Florida · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1034

Site Number - 1037

Ormond Beach · Florida · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1035

Site Number - 1002

Port Charlotte · Florida · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1036

Site Number - 1050

Rockledge · Florida · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1037

Site Number - 1007

Tampa · Florida · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1038

Site Number - 1014

Atlanta · Georgia · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1039

Site Number - 1043

Augusta · Georgia · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1040

Site Number - 1054

Schaumburg · Illinois · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1041

Site Number - 1022

Lexington · Kentucky · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1042

Site Number - 1032

Nicholasville · Kentucky · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1043

Site Number - 1046

New Orleans · Louisiana · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1044

Site Number - 1049

Foxborough · Massachusetts · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1045

Site Number - 1026

Detroit · Michigan · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1046

Site Number - 1005

East Lansing · Michigan · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1047

Site Number - 1018

Omaha · Nebraska · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1048

Site Number - 1019

Totowa · New Jersey · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1049

Site Number - 1036

New York · New York · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1050

Site Number - 1034

New York · New York · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1051

Site Number - 1020

Chapel Hill · North Carolina · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1052

Site Number - 1013

Durham · North Carolina · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1053

Site Number - 1044

Raleigh · North Carolina · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1054

Site Number - 1038

Cincinnati · Ohio · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1055

Site Number - 1045

Oklahoma City · Oklahoma · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1056

Site Number - 1011

Yukon · Oklahoma · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1057

Site Number - 1031

Eugene · Oregon · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1058

Site Number - 1030

Charleston · South Carolina · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1059

Site Number - 1015

Charleston · South Carolina · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1060

Site Number - 1021

Memphis · Tennessee · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1061

Site Number - 1003

Dallas · Texas · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1062

Site Number - 1047

Denton · Texas · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1063

Site Number - 1057

Houston · Texas · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1064

Site Number - 1048

Lubbock · Texas · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1065

Site Number - 1009

Charlottesville · Virginia · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1066

Site Number - 1040

Richmond · Virginia · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1067

Site Number - 1035

Greenfield · Wisconsin · United States

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1068

Site Number - 5003

Caba · Argentina

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1069

Site Number - 5002

Rosario · Argentina

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1070

Site Number - 3201

Brno · Czechia

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1071

Site Number - 3601

Copenhagen · Denmark

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1072

Site Number - 8002

Tbilisi · Georgia

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1073

Site Number - 8003

Tbilisi · Georgia

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1074

Site Number - 8001

Tbilisi · Georgia

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1075

Site Number - 6502

Bochum · Germany

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1076

Site Number - 6504

Goettigen · Germany

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1077

Site Number - 6505

Magdeburg · Germany

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1078

Site Number - 6503

Würzburg · Germany

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1079

Site Number - 3903

Athens · Greece

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1080

Site Number - 3902

Athens · Greece

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1081

Site Number - 3901

Pátrai · Greece

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1082

Site Number - 3904

Thessaloniki · Greece

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1083

Site Number - 7552

Budapest · Hungary

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1084

Site Number - 7553

Budapest · Hungary

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1085

Site Number - 7551

Kistarcsa · Hungary

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1086

Site Number - 6003

Bergamo · Italy

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1087

Site Number - 6002

Milan · Italy

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1088

Site Number - 6001

Naples · Italy

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1089

Site Number - 6004

Rome · Italy

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1090

Site Number - 2602

Mexico City · Mexico

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1091

Site Number - 3005

Gdansk · Poland

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1092

Site Number - 3001

Katowice · Poland

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1093

Site Number - 3006

Krakow · Poland

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1094

Site Number - 3002

Krakow · Poland

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1095

Site Number - 3003

Krakow · Poland

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1096

Site Number - 3004

Lublin · Poland

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1097

Site Number - 3007

Warsaw · Poland

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1098

Site Number - 7502

Constanța · Romania

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1099

Site Number - 7501

Târgu Mureş · Romania

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1100

Site Number - 9001

Belgrade · Serbia

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1101

Site Number - 9002

Niš · Serbia

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1102

Site Number - 7103

Barcelona · Spain

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1103

Site Number - 7101

Córdoba · Spain

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1104

Site Number - 7104

Madrid · Spain

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1105

Site Number - 7003

Birmingham · United Kingdom

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1106

Site Number - 7002

Glasgow · United Kingdom

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1107

Site Number - 7004

London · United Kingdom

1 trial

IMVT-1402 drug tested for safety and effectiveness in adults with generalized myasthenia gravis.

Immunovant Sciences GmbHPh 3RecruitingNCT07039916 ↗

1108

Valley Clinical Trials, Inc.

Northridge · California · United States

1 trial

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗

1109

Merritt Island Medical Research, LLC

Merritt Island · Florida · United States

1 trial

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗

1110

Clinical Site Partners, LLC dba Flourish Research

Winter Park · Florida · United States

1 trial

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗

1111

Massachusetts General Hospital

Boston · Massachusetts · United States

1 trial

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

1112

Profound Research LLC

Farmington Hills · Michigan · United States

1 trial

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗

1113

Virginia Heart - Leesburg

Leesburg · Virginia · United States

1 trial

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

1114

University of the Sunshine Coast (UniSC) Clinical Trials - Birtinya

Birtinya · Australia

1 trial

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

1115

Top Moravia Health

Brno · Czechia

1 trial

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

1116

Szabolcs Szatmár Bereg Vármegyei Oktatókórház

Nyíregyháza · Hungary

1 trial

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

1117

Medisch Spectrum Twente

Enschede · Netherlands

1 trial

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

1118

Alrijne Ziekenhuis, locatie Leiderdorp

Leiderdorp · Netherlands

1 trial

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

1119

Hospital Quiron Barcelona

Barcelona · Spain

1 trial

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

1120

FutureMeds - Birmingham

Birmingham · United Kingdom

1 trial

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

1121

Royal Lancaster Infirmary

Lancaster · United Kingdom

1 trial

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

1122

Lincoln County Hospital

Lincoln · United Kingdom

1 trial

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

1123

Futuremeds-Newcastle

Newcastle · United Kingdom

1 trial

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

1124

The John Radcliffe Hospital

Oxford · United Kingdom

1 trial

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

1125

Sheffield Teaching Hospitals NHS Foundation Trust

Sheffield · United Kingdom

1 trial

Lepodisiran injection tested to reduce artery plaque in high-risk adults with elevated lipoprotein(a).

Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗

1126

Novartis Investigative Site

Hefei · Anhui · China

1 trial

Inclisiran drug tested to shrink heart artery plaque in heart attack patients with high cholesterol.

Novartis PharmaceuticalsPh 4NCT06372925 ↗

1127

Novartis Investigative Site

Fuzhou · Fujian · China

1 trial

Inclisiran drug tested to shrink heart artery plaque in heart attack patients with high cholesterol.

Novartis PharmaceuticalsPh 4NCT06372925 ↗

1128

Novartis Investigative Site

Shenzhen · Guangdong · China

1 trial

Inclisiran drug tested to shrink heart artery plaque in heart attack patients with high cholesterol.

Novartis PharmaceuticalsPh 4NCT06372925 ↗

1129

Novartis Investigative Site

Zunyi · Guizhou · China

1 trial

Inclisiran drug tested to shrink heart artery plaque in heart attack patients with high cholesterol.

Novartis PharmaceuticalsPh 4NCT06372925 ↗

1130

Novartis Investigative Site

Zhengzhou · Henan · China

1 trial

Inclisiran drug tested to shrink heart artery plaque in heart attack patients with high cholesterol.

Novartis PharmaceuticalsPh 4NCT06372925 ↗

1131

Novartis Investigative Site

Wuhan · Hubei · China

1 trial

Inclisiran drug tested to shrink heart artery plaque in heart attack patients with high cholesterol.

Novartis PharmaceuticalsPh 4NCT06372925 ↗

1132

Novartis Investigative Site

Nanchang · Jiangxi · China

1 trial

Inclisiran drug tested to shrink heart artery plaque in heart attack patients with high cholesterol.

Novartis PharmaceuticalsPh 4NCT06372925 ↗

1133

UC San Francisco Medical Center

San Francisco · California · United States

1 trial

Inclisiran drug safety and effectiveness evaluated in young children with severe inherited high cholesterol.

Novartis PharmaceuticalsPh 3RecruitingNCT06597006 ↗

1134

Childrens National Hospital

Washington D.C. · District of Columbia · United States

1 trial

Inclisiran drug safety and effectiveness evaluated in young children with severe inherited high cholesterol.

Novartis PharmaceuticalsPh 3RecruitingNCT06597006 ↗

1135

Primary Childrens Medical Center

Salt Lake City · Utah · United States

1 trial

Inclisiran drug safety and effectiveness evaluated in young children with severe inherited high cholesterol.

Novartis PharmaceuticalsPh 3RecruitingNCT06597006 ↗

1136

Novartis Investigative Site

Kota Bharu · Kelantan · Malaysia

1 trial

Inclisiran drug safety and effectiveness evaluated in young children with severe inherited high cholesterol.

Novartis PharmaceuticalsPh 3RecruitingNCT06597006 ↗

1137

Novartis Investigative Site

Bloemfontein · Free State · South Africa

1 trial

Inclisiran drug safety and effectiveness evaluated in young children with severe inherited high cholesterol.

Novartis PharmaceuticalsPh 3RecruitingNCT06597006 ↗

1138

Novartis Investigative Site

Johannesburg · Gauteng · South Africa

1 trial

Inclisiran drug safety and effectiveness evaluated in young children with severe inherited high cholesterol.

Novartis PharmaceuticalsPh 3RecruitingNCT06597006 ↗

1139

Novartis Investigative Site

Adana · Saricam · Turkey (Türkiye)

1 trial

Inclisiran drug safety and effectiveness evaluated in young children with severe inherited high cholesterol.

Novartis PharmaceuticalsPh 3RecruitingNCT06597006 ↗

1140

Novartis Investigative Site

Southampton · United Kingdom

1 trial

Inclisiran drug safety and effectiveness evaluated in young children with severe inherited high cholesterol.

Novartis PharmaceuticalsPh 3RecruitingNCT06597006 ↗

1141

Pinnacle Research Group

Anniston · Alabama · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1142

Cullman Clinical Trials

Cullman · Alabama · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1143

Anaheim Clinical Trials

Anaheim · California · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1144

Cenexel CNS

Los Alamitos · California · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1145

Diablo Clinical Research - Flourish Research

Walnut Creek · California · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1146

Tampa Bay Medical Research

Clearwater · Florida · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1147

Southwest General Healthcare Center

Fort Myers · Florida · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1148

Precision Clinical Research

Sunrise · Florida · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1149

K2 Medical Research The Villages

The Villages · Florida · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1150

Center for Advanced Research and Education

Gainesville · Georgia · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1151

Balanced Life Health Care Solutions

Lawrenceville · Georgia · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1152

East-West Medical Research Institute

Honolulu · Hawaii · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1153

L-MARC Research Center

Louisville · Kentucky · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1154

Tandem Clinical Research

Marrero · Louisiana · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1155

Velocity Clinical Research - Omaha

Omaha · Nebraska · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1156

Palm Research Center, Mountainview Medical Center

Las Vegas · Nevada · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1157

Velocity Clinical Research - Durham

Durham · North Carolina · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1158

Accellacare of Wilmington

Wilmington · North Carolina · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1159

Ohio Clinical Trials

Columbus · Ohio · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1160

AMR Norman

Norman · Oklahoma · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1161

Lynn Health Science Institute

Oklahoma City · Oklahoma · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1162

Velocity Clinical Research, Medford

Medford · Oregon · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1163

Tribe Clinical Research

Greenville · South Carolina · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1164

Coastal Carolina Research Center_North Charleston

North Charleston · South Carolina · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1165

Velocity Clinical Research Dallas

Dallas · Texas · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1166

Valley Institute of Research, Rockwood Medical Clinic

Fort Worth · Texas · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1167

Be Well Clinical Studies - Round Rock

Round Rock · Texas · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1168

Flourish Research - San Antonio Medical Trials

San Antonio · Texas · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1169

Charlottesville Medical Research

Charlottesville · Virginia · United States

1 trial

Alirocumab weekly injections reduce cholesterol in adults with high blood cholesterol levels.

Regeneron PharmaceuticalsPh 2RecruitingNCT07477704 ↗

1170

Alliance for Multispecialty Research, LLC

Daphne · Alabama · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1171

SEC Clinical Research

Dothan · Alabama · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1172

Alliance for Multispecialty Research, LLC

Mobile · Alabama · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1173

Sun City Clinical Research

Glendale · Arizona · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1174

Elite Clinical Studies, LLC

Phoenix · Arizona · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1175

Helios Clinical Research - Phoenix

Phoenix · Arizona · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1176

Absolute Clinical Research

Phoenix · Arizona · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1177

Synexus Clinical Research US, Inc./Orange Grove Family Practice

Tucson · Arizona · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1178

Cardiology and Medicine Clinic

Little Rock · Arkansas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1179

Valley Clinical Trials, Inc.

Covina · California · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1180

HB Clinical Trials - Fountain Valley

Fountain Valley · California · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1181

First Valley Medical Group

Lancaster · California · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1182

MemorialCare Health System - Long Beach Medical Center

Long Beach · California · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1183

Ark Clinical Research

Long Beach · California · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1184

Keck School of Medicine of USC

Los Angeles · California · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1185

Cardiovascular Research Foundation of Southern California

Los Angeles · California · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1186

Valley Clinical Trials, LLC dba Flourish Research

Northridge · California · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1187

Desert Oasis Healthcare Medical Group

Palm Springs · California · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1188

Artemis Institute for Clinical Research

San Diego · California · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1189

Care Access - Santa Clarita

Santa Clarita · California · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1190

Stanford University Medical Center

Stanford · California · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1191

Olive View-UCLA Medical Center

Sylmar · California · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1192

Care Access - Thousand Oaks

Thousand Oaks · California · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1193

Med Partners, Inc. dba Premiere Medical Center of Burbank, Inc.

Toluca Lake · California · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1194

InvivoCure

Van Nuys · California · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1195

Synexus Clinical Research US, Inc.

Vista · California · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1196

Millennium Clinical Trials

Westlake Village · California · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1197

CMR of Greater New Haven, LLC

Hamden · Connecticut · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1198

Hartford Hospital (HH)

Hartford · Connecticut · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1199

MedStar Washington Hospital Center

Washington D.C. · District of Columbia · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1200

Clearwater Cardiovascular & Interventional Consultants M.D., P.A.

Clearwater · Florida · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1201

Clinical Research of West Florida, Inc. (Clearwater)

Clearwater · Florida · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1202

Elite Cardiac Research Center

Hialeah · Florida · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1203

Westside Center for Clinical Research

Jacksonville · Florida · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1204

Clearwater Cardiovascular & Interventional Consultants M.D., P.A.

Largo · Florida · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1205

South Florida Clinical Research Institute

Margate · Florida · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1206

Flourish Research - Miami, LLC

Miami · Florida · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1207

CTR Oakwater, LLC

Orlando · Florida · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1208

Florida Institute For Clinical Research, LLC

Orlando · Florida · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1209

Innovative Research Institute - Port Charlotte

Port Charlotte · Florida · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1210

Clearwater Cardiovascular & Interventional Consultants M.D., P.A.

Safety Harbor · Florida · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1211

Clinical Research of West Florida

Tampa · Florida · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1212

Cardiology Partners Clinical Research Institute - Wellington

Wellington · Florida · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1213

American Clinical Trials - Acworth

Acworth · Georgia · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1214

Atlanta Diabetes Associates

Atlanta · Georgia · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1215

Emory University School of Medicine

Atlanta · Georgia · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1216

East Coast Institute for Research - Canton

Canton · Georgia · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1217

American Clinical Trials - Douglasville

Douglasville · Georgia · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1218

Georgia Clinical Research - Lawrenceville

Lawrenceville · Georgia · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1219

The Jones Center Clinical Research

Macon · Georgia · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1220

CARE Institute

Meridian · Idaho · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1221

Chicago Clinical Research Institute

Chicago · Illinois · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1222

Alliance for Multispecialty Research, LLC

Niles · Illinois · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1223

Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative

Springfield · Illinois · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1224

Accellacare - DuPage

Winfield · Illinois · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1225

American Health Network of Indiana, LLC - Avon

Avon · Indiana · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1226

Care Access - South Indianapolis

Indianapolis · Indiana · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1227

American Health Network of Indiana, LLC - Franklin

Whiteland · Indiana · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1228

Iowa Diabetes and Endocrinology Research Center

West Des Moines · Iowa · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1229

Cotton O'Neil Clinical Research Center

Topeka · Kansas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1230

AMR Clinical

Wichita · Kansas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1231

Qualmedica Research

Bowling Green · Kentucky · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1232

Alliance for Multispecialty Research, LLC

Lexington · Kentucky · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1233

Grace Research - Bossier

Bossier City · Louisiana · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1234

Care Access - Lake Charles

Lake Charles · Louisiana · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1235

Alliance for Multispecialty Research, LLC

New Orleans · Louisiana · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1236

Louisiana Heart Center - Slidell

Slidell · Louisiana · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1237

Sinai Hospital Of Baltimore

Baltimore · Maryland · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1238

Care Access - Baltimore

Baltimore · Maryland · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1239

MedStar Good Samaritan Hospital

Baltimore · Maryland · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1240

Jadestone Clinical Research

Beltsville · Maryland · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1241

Kur Research - Columbia Medical

Columbia · Maryland · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1242

MedStar Health Research Institute (MedStar Physician Based Research Network)

Hyattsville · Maryland · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1243

NECCR PrimaCare Research

Fall River · Massachusetts · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1244

Alliance for Multispecialty Research, LLC.

Dearborn · Michigan · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1245

Michigan Heart & Vascular Institute

Ypsilanti · Michigan · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1246

Memorial Hospital at Gulfport

Diamondhead · Mississippi · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1247

Clinvest Headlands Llc

Springfield · Missouri · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1248

Las Vegas Endocrinology

Henderson · Nevada · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1249

DaVita Clinical Research - Las Vegas

Las Vegas · Nevada · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1250

Palm Research Center Tenaya

Las Vegas · Nevada · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1251

Internal Medicine Associates

Bridgeton · New Jersey · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1252

Atlantic Health System Overlook Medical Center

Summit · New Jersey · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1253

IMA Clinical Research Warren

Warren Township · New Jersey · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1254

Albany Medical College, Division of Community Endocrinology

Albany · New York · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1255

St. Francis Hospital & Heart Center

New Hyde Park · New York · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1256

NYU Langone Health

New York · New York · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1257

University of Rochester Medical Center

Rochester · New York · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1258

Saratoga Clinical Research

Saratoga Springs · New York · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1259

Stony Brook University

Stony Brook · New York · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1260

Triad Clinical Trials

Greensboro · North Carolina · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1261

Physician's East Endocrinology

Greenville · North Carolina · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1262

IMA Clinical Research Mount Airy

Mount Airy · North Carolina · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1263

Accellacare - Raleigh

Raleigh · North Carolina · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1264

Accellacare - Wilmington

Wilmington · North Carolina · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1265

Wake Forest Baptist Health

Winston-Salem · North Carolina · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1266

Velocity Clinical Research, Cleveland

Beachwood · Ohio · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1267

Velocity Clinical Research, Mt. Auburn

Cincinnati · Ohio · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1268

Velocity Clinical Research, Springdale

Cincinnati · Ohio · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1269

Cleveland Clinic

Cleveland · Ohio · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1270

Centricity Research Columbus Ohio Multispecialty

Columbus · Ohio · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1271

Good Samaritan Regional Medical Center

Corvallis · Oregon · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1272

Heritage Valley Multispecialty Group, Inc

Beaver · Pennsylvania · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1273

Abington Medical Specialists

Horsham · Pennsylvania · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1274

Lancaster General Hospital

Lancaster · Pennsylvania · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1275

AHN Allegheny General Hospital

Pittsburgh · Pennsylvania · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1276

Preferred Primary Care Physicians

Uniontown · Pennsylvania · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1277

Accellacare Trident Cardiology

Charleston · South Carolina · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1278

Tribe Clinical Research, LLC

Greenville · South Carolina · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1279

Care Access - Mauldin

Mauldin · South Carolina · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1280

Accellacare - Mt Pleasant

Mt. Pleasant · South Carolina · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1281

Monument Health Rapid City Hospital

Rapid City · South Dakota · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1282

Alliance for Multispecialty Research, LLC

Knoxville · Tennessee · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1283

Care Access - Memphis 2

Memphis · Tennessee · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1284

Amarillo Heart Clinical Research Institute Inc.

Amarillo · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1285

IMA Clinical Research Austin

Austin · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1286

Headlands Horizons LLC

Brownsville · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1287

South Texas Clinical Research

Corpus Christi · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1288

Private Practice - Dr. James E. Race

Dallas · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1289

Baylor Soltero CV Research Center

Dallas · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1290

Cedar Health Research

Dallas · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1291

Cardio Voyage

Denison · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1292

South Texas Research Institute

Edinburg · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1293

Juno Research

Houston · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1294

Biopharma Informatic, LLC

Houston · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1295

PlanIt Research, PLLC

Houston · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1296

Accurate Clinical Research - Humble

Humble · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1297

The Heart Institute of East Texas

Lufkin · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1298

Wellness Clinical Research

McKinney · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1299

North Texas Research Associates

McKinney · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1300

Texas Institute of Cardiology, PA

McKinney · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1301

Southern Endocrinology Associates

Mesquite · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1302

Clinical Advancement Center

San Antonio · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1303

Clinical Trials of Texas, LLC

San Antonio · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1304

DaVita Clinical Research - North Houston

Shenandoah · Texas · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1305

Alpine Research Organization

Clinton · Utah · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1306

Alliance for Multispecialty Research, LLC

Norfolk · Virginia · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1307

IMA Clinical Research West Virginia

Morgantown · West Virginia · United States

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1308

Clínica Privada del Prado SRL

Alberdi · Argentina

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1309

Fundación favaloro para la Docencia e Investigación Médica

Buenos Aires · Argentina

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1310

CEDIC

CABA · Argentina

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1311

Sanatorio Privado Duarte Quirós

Córdoba · Argentina

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1312

CIDIM-Centro Integral de Diagnostico por Imagenes Marchegiani

Córdoba · Argentina

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1313

MICA - Medicina e Investigación Cardiometabólica

Del Viso · Argentina

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1314

Hospital Italiano de La Plata

La Plata · Argentina

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1315

Clínica Privada Independencia

Munro · Argentina

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1316

Centro Privado de Medicina Respiratoria

Paraná · Argentina

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1317

CER medical Institute

Quilmes · Argentina

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1318

Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica

Rosario · Argentina

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1319

Centro Cardiovascular Salta

Salta · Argentina

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1320

Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L

San Miguel de Tucumán · Argentina

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1321

Go Centro Medico San Nicolás

San Nicolás · Argentina

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1322

Clínica de Nefrología, Urología y Enfermedades Cardiovasculares

Santa Fe · Argentina

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1323

Sanatorio San Martin

Venado Tuerto · Argentina

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1324

Advara HeartCare Leabrook

Adelaide · Australia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1325

Paratus Clinical Research Western Sydney

Blacktown · Australia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1326

Emeritus Research

Botany · Australia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1327

Paratus Clinical Research Canberra

Bruce · Australia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1328

Emeritus Research

Camberwell · Australia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1329

Austin Health - Repatriation Hospital

Heidelberg West · Australia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1330

Paratus Clinical Research Brisbane

Herston · Australia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1331

Paratus Clinical Research Central Coast

Kanwal · Australia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1332

Liverpool Hospital

Liverpool · Australia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1333

Logan Hospital

Meadowbrook · Australia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1334

AusTrials - Sunshine

Melbourne · Australia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1335

University of the Sunshine Coast (UniSC) Clinical Trials - Noosa

Noosaville · Australia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1336

Royal Perth Hospital

Perth · Australia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1337

Momentum St. Leonards

Sydney · Australia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1338

Townsville University Hospital

Townsville · Australia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1339

Medizinische Universitaet Innsbruck

Innsbruck · Austria

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1340

Université Libre de Bruxelles - Hôpital Erasme

Brussels · Belgium

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1341

Grand Hôpital de Charleroi

Charleroi · Belgium

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1342

AZ Sint-Blasius

Dendermonde · Belgium

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1343

AZ Maria Middelares

Ghent · Belgium

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1344

UZ Gent

Ghent · Belgium

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1345

Jessa Ziekenhuis

Hasselt · Belgium

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1346

Instituto Aramari Apo

Asa Norte · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1347

Santa Casa de Misericordia de Belo Horizonte

Belo Horizonte · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1348

Freire Pesquisa Clínica

Belo Horizonte · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1349

L2IP - Instituto de Pesquisas Clínicas

Brasília · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1350

Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Brasília

Brasília · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1351

PUC Trials- Nucleo de Pesquisa clinica da Escola de Medicina da PUCPR

Curitiba · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1352

Nucleo De Pesquisa Clinica

Curitiba · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1353

Centro de Pesquisas Clínicas Dr. Marco Mota

Maceió · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1354

CHN - Complexo Hospitalar de Niterói

Niterói · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1355

Hospital São Lucas da PUCRS

Porto Alegre · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1356

CAPED Centro Avancado Pesquisa e Diagnostica

Ribeirão Preto · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1357

Instituto D'Or Pesquisa e Ensino

Rio de Janeiro · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1358

Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Salvador

Salvador · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1359

Hospital Ana Nery (HAN) - Salvador

Salvador · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1360

Hospital Da Bahia

Salvador · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1361

Faculdade de Medicina do ABC

Santo André · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1362

Centro Multidisciplinar de Estudos Clinicos

São Bernardo do Campo · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1363

BP - A Beneficencia Portuguesa de São Paulo

São Paulo · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1364

Hospital Alemao Oswaldo Cruz

São Paulo · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1365

Hospital do Coracao

São Paulo · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1366

IBCC - Núcleo de Pesquisa e Ensino

São Paulo · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1367

Instituto de Molestias Cardiovasculares de Tatui

Tatuí · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1368

Eurolatino Pesquisas Medicas

Uberlândia · Brazil

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1369

Cardio Health Clinical Trial - Brampton

Brampton · Canada

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1370

Milestone Research Inc.

London · Canada

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1371

Cardio Health Clinical Trial - London

London · Canada

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1372

Fraser Clinical Trials Inc

New Westminster · Canada

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1373

The Medical Arts Health Research Group

North Vancouver · Canada

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1374

Oakville Cardiovascular Research LP

Oakville · Canada

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1375

Medical Arts Health Research Group

Penticton · Canada

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1376

Clinique des Maladies Lipidiques de Québec

Québec · Canada

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1377

ALPHA Recherche Clinique

Québec · Canada

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1378

Unité de Recherche Clinique du CISSS des Laurentides

Saint-Jérôme · Canada

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1379

Cardio Health Clinical Trial - St. Thomas

St. Thomas · Canada

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1380

SMH Cardiology Clinical Trials

Surrey · Canada

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1381

Care Access - Cape Breton

Sydney · Canada

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1382

Centre de Medecine Metabolique de Lanaudiere (CMML)

Terrebonne · Canada

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1383

Corcare

Toronto · Canada

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1384

Diabetes Heart Research Centre

Toronto · Canada

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1385

ARC Biosystems

Vancouver · Canada

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1386

Winnipeg Clinic

Winnipeg · Canada

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1387

Beijing Chaoyang Hospital, Capital Medical University

Beijing · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1388

Beijing Friendship Hospital Affiliate of Capital University

Beijing · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1389

The Third Xiangya Hospital of Central South University

Changsha · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1390

Changzhou Second People's Hospital

Changzhou · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1391

Chifeng Hospital

Chifeng · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1392

Dalian Municipal Central Hospital Affiliated of Dalian Medical University

Dalian · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1393

Shunde Hospital of Southern Medical Univesity

Foshan · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1394

Guangzhou First People's Hospital

Guangzhou · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1395

The Fourth Affiliated Hospital of Harbin Medical University

Harbin · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1396

Inner Mongolia People's Hospital

Hohhot · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1397

Huizhou Municipal Central Hospital

Huizhou · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1398

Jingzhou Central Hospital

Jingzhou · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1399

The First Hospital of Lanzhou University

Lanzhou · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1400

The Second Affiliated Hospital of Nanchang University

Nanchang · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1401

The Third Hospital of Nanchang

Nanchang · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1402

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School

Nanjing · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1403

The Second Affiliated Hospital of Nanjing Medical University

Nanjing · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1404

Guangxi People's Hospital

Nanning · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1405

Nanyang Second General Hospital

Nanyang · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1406

The First Affiliated Hospital of Nanyang Medical College

Nanyang · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1407

Ningbo First Hospital

Ningbo · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1408

Ruijin Hospital Shanghai Jiaotong University School of Medicine

Shanghai · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1409

Shanghai Putuo District Center Hospital

Shanghai · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1410

Shanghai East Hospital

Shanghai · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1411

Shanghai No. 6 People's Hospital - Jinshan Central Hospital

Shanghai · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1412

The People's Hospital of Liaoning Province

Shenyang · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1413

Shenzhen Sun Yat-sen Cardiovascular Hospital

Shenzhen · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1414

The First Affiliated Hospital of Soochow University

Suzhou · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1415

Tianjin Fourth Centre Hospital

Tianjin · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1416

TEDA International Cardiovascular Hospital

Tianjin · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1417

The First Affiliated Hospital of Xinjiang Medical University

Ürümqi · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1418

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1419

Wuhan University Medical College - Hubei Zhongshan Hospital

Wuhan · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1420

Wuhan Asia Heart Hospital

Wuhan · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1421

Wuxi People's Hospital

Wuxi · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1422

Tangdu Hospital of Fourth Military Medical University of Chinese People's Liberation Army

Xi'an · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1423

The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1424

Xiamen Cardiovascular Hospital

Xiamen · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1425

General Hospital of Ningxia Medical University

Yinchuan · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1426

The First People's Hospital of Yueyang

Yueyang · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1427

The Second Affiliated Hospital of Zhengzhou University

Zhengzhou · China

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1428

MEDICUS SERVICES s.r.o., kardiologicka ambulance

Brandýs nad Labem · Czechia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1429

Vojenská Nemocnice Brno

Brno · Czechia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1430

Kardiologicka ambulance

Litovel · Czechia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1431

EDUMED - Náchod

Náchod · Czechia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1432

Agentura Science Pro

Olomouc · Czechia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1433

PreventaMed

Olomouc · Czechia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1434

Kardiologicka a Angiologicka Ambulance

Ostrava · Czechia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1435

Private Practice - Dr. Miroslav Koliba

Ostrava · Czechia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1436

Kardio Uhrineves

Prague · Czechia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1437

Synexus Czech

Prague · Czechia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1438

Nefrologie

Prague · Czechia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1439

Centrum Kardiovaskularni Mediciny

Prague · Czechia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1440

Nova kardiologie - Kardiologicka ambulance

Říčany · Czechia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1441

Kardiologicka ambulance MUDr. Ferkl s.r.o.

Trutnov · Czechia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1442

Clinical Trials Service s.r.o.

Uherské Hradiště · Czechia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1443

Sygehus Sønderjylland i Aabenraa

Aabenraa · Denmark

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1444

Aarhus Universitetshospital, Skejby

Aarhus · Denmark

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1445

Rigshospitalet

Copenhagen · Denmark

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1446

Esbjerg sygehus, Syddansk Universitetshospital

Esbjerg · Denmark

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1447

Herlev and Gentofte Hospital

Herlev · Denmark

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1448

Holbæk Sygehus

Holbæk · Denmark

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1449

Hôpital Avicenne

Bobigny · France

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1450

Hospices Civils de Lyon - Hopital Louis Pradel

Bron · France

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1451

CHRU Troussau

Chambray-lès-Tours · France

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1452

Centre Hospitalier Compiègne-Noyon

Compiègne · France

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1453

Centre Hospitalier Louis Pasteur

Le Coudray · France

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1454

Hôpital de la Conception

Marseille · France

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1455

Hôpital Saint Joseph

Marseille · France

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1456

CHU Montpellier Lapeyronie Hospital

Montpellier · France

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1457

Centre Hospitalier Universitaire de Nîmes - Hôpital Universitaire Carémeau

Nîmes · France

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1458

Centre Hospitalier de Pau

Pau · France

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1459

CHU Bordeaux Haut-Leveque

Pessac · France

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1460

Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou

Rennes · France

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1461

CHU Charles Nicolle

Rouen · France

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1462

Polyclinique Vauban

Valenciennes · France

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1463

Klinikum am Plattenwald

Bad Friedrichshall · Germany

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1464

Praxis Rankestrasse

Berlin · Germany

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1465

DRK Kliniken Berlin - Köpenick

Berlin · Germany

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1466

Klinikum Bielefeld Mitte

Bielefeld · Germany

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1467

Universitaetsklinikum Koeln

Cologne · Germany

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1468

Medizentrum Essen Borbeck

Essen · Germany

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1469

BAG Diabeteszentrum Dr. Tews & Partner

Gelnhausen · Germany

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1470

Universitätsklinikum Jena

Jena · Germany

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1471

Universitätsmedizin Mannheim

Mannheim · Germany

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1472

Kardiologische Gemeinschaftspraxis am Park Sanssouci

Potsdam · Germany

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1473

Universitaet zu Koeln - Sana-Klinikum Remscheid GmbH - Klinik fuer Kardiologie, Pneumologie und Internisti -T

Remscheid · Germany

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1474

GPR Gesundheits- und Pflegezentrum Rüsselsheim

Rüsselsheim am Main · Germany

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1475

Zentrum für klinische Studien

Saint Ingbert · Germany

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1476

Athens Naval Hospital

Athens · Greece

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1477

General Hospital of Athens Laiko

Athens · Greece

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1478

Athens Medical Center

Athens · Greece

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1479

Attikon General University Hospital

Chaïdári · Greece

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1480

Iatriko Paleou Falirou Medical Center

Palaió Fáliro · Greece

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1481

Papageorgiou General Hospital of Thessaloniki

Thessaloniki · Greece

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1482

DRC Gyógyszervizsgáló Központ

Balatongyörök · Hungary

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1483

Privát Doktor Egészségügyi Zrt

Budapest · Hungary

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1484

Eszak-Pesti Centrumkorhaz-Honvedkorhaz

Budapest · Hungary

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1485

Debreceni Egyetem Klinikai Kozpont

Debrecen · Hungary

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1486

Sardar Patel Medical College

Bikaner · India

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1487

Shri Mahant Indiresh Hospital

Dehradun · India

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1488

Lisie Hospital

Kochi · India

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1489

Emek Medical Center

Afula · Israel

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1490

Soroka Medical Center

Beersheba · Israel

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1491

Rambam Health Care Campus

Haifa · Israel

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1492

Carmel Hospital

Haifa · Israel

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1493

Linn Medical Center

Haifa · Israel

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1494

Edith Wolfson Medical Center

Holon · Israel

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1495

Shaare Zedek Medical Center

Jerusalem · Israel

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1496

Hadassah Medical Center

Jerusalem · Israel

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1497

Meir Medical Center

Kfar Saba · Israel

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1498

Galilee Medical Center

Nahariya · Israel

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1499

Rabin Medical Center

Petah Tikva · Israel

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1500

Sheba Medical Center

Ramat Gan · Israel

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1501

Kaplan Medical Center

Rehovot · Israel

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1502

Clalit Health Services - Sakhnin Community Clinic

Sakhnin · Israel

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1503

Sourasky Medical Center

Tel Aviv · Israel

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1504

Ospedale Bassini

Cinisello Balsamo · Italy

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1505

AOU Policlinico Umberto I

Rome · Italy

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1506

Asahi Hospital - Asahi

Asahi · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1507

Asahikawa City Hospital

Asahikawa · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1508

Saiseikai Futsukaichi Hospital

Chikushino-shi · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1509

University of Yamanashi Hospital

Chūō · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1510

Tokyo-Eki Center-building Clinic

Chūōku · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1511

Fukuwa Clinic

Chūōku · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1512

Fukuoka Wajiro Hospital

Fukuoka · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1513

Public Matto Ishikawa Central Hospital

Hakusan · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1514

Hyogo Prefectural Harima-Himeji General Medical Center

Himeji · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1515

Tokai University Hospital

Isehara · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1516

Rinku General Medical Center

Izumisano · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1517

Takai Internal Medicine Clinic

Kamakura-shi · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1518

Ishikawa Prefectural Central Hospital

Kanazawa · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1519

National Hospital Organization Kanazawa Medical Center

Kanazawa · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1520

Kasugai Municipal Hospital

Kasugai · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1521

Kokura Memorial Hospital

Kitakyushu · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1522

Kobe City Medical Center General Hospital

Kobe · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1523

Komatsu Municipal Hospital

Komatsu · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1524

Jinnouchi Hospital

Kumamoto · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1525

Kurashiki Central Hospital

Kurashiki · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1526

Chugoku Rosai Hospital

Kure · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1527

Rakuwakai Marutamachi Hospital

Kyoto · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1528

Rakuwakai Otowa Hospital

Kyoto · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1529

Aizawa Hospital

Matsumoto · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1530

National Hospital Organization Tokyo Medical Center

Meguro-ku · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1531

Tokyo Saiseikai Central Hospital

Minatoku · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1532

Miyakonojo Medical Association Hospital - Tarobocho

Miyakonojō · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1533

Kanazawa Medical University Hospital

Mukai-awagasaki · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1534

Tachikawa Medical Center

Nagaoka · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1535

Shonan Oiso Hospital

Naka-gun · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1536

Nogata Clinic

Nakano · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1537

Okayama City General Medical Center Okayama City Hospital

Okayama · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1538

National Hospital Organization Okayama Medical Center

Okayama · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1539

Medical Corporation Sato Medical clinic

Ootaku · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1540

National Hospital Organization - Osaka National Hospital - Institute For Clinical Research

Osaka · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1541

Kansai Electric Power Hospital

Osaka · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1542

Osaki Citizen Hospital - Furukawahonami

Ōsaki · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1543

Saga University Hospital

Saga · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1544

Kitasato University Hospital

Sagamihara · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1545

Sanai Hospital - Saitama

Saitama · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1546

Tokeidai Memorial Hospital

Sapporo · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1547

Heishinkai Medical Group ToCROM Clinic

Shinjuku-ku · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1548

National Center for Global Health and Medicine

Shinjyuku-ku · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1549

Medical Corporation Heishinkai OCROM Clinic

Suita-shi · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1550

Shizuoka Medical Center

Sunto-gun · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1551

Higashi Takarazuka Satoh Hospital

Takarazuka · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1552

Takasago Seibu Hospital

Takasago · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1553

National Hospital Organization Shinshu Ueda Medical Center

Ueda · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1554

Saiseikai Yokohamashi Tobu Hospital

Yokohama · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1555

Yokosukakyosai

Yokosuka · Japan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1556

Centro de Investigación Cardiometabólica de Aguascalientes

Aguascalientes · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1557

Hospital Cardiologica Aguescalientes

Aguascalientes · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1558

Enclifar Ensayos Clínicos Farmacológicos Sc

Chihuahua City · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1559

Lahoja. Asociacion Para La Investigacion Y La Farmacovigilancia

Durango · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1560

Diseno y Planeacion en Investigacion Medica

Guadalajara · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1561

Centro de Investigacion Medica Integral

Guadalajara · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1562

CINVEC Medica

Guadalajara · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1563

Investigación Médica Sonora, S.C.

Hermosillo · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1564

RM Pharma Specialists

Mexico City · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1565

Clínicos Asociados BOCM

Mexico City · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1566

Clinica Omega

Mexico City · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1567

Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares

Mexico City · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1568

ProcliniQ Investigación Clínica SA de CV

Mexico City · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1569

Clinstile, S.A. de C.V.

México · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1570

Christus - Latam Hub Center of Excellence and Innovation S.C.

Monterrey · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1571

Hospital Universitario "Dr. Jose Eleuterio Gonzalez"

Monterrey · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1572

Clinica de Enfermedades Crónicas y de Procedimientos Especiales

Morelia · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1573

Centro de Estudios Clínicos de Querétaro (CECLIQ)

Querétaro · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1574

PanAmerican Clinical Research - Querétaro - Avenida Antea

Querétaro · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1575

Centro de Investigacion Cardiovascular y Metabólica

Tijuana · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1576

Instituto Veracruzano en Investigación Clínica S.C.

Veracruz · Mexico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1577

Gelre Ziekenhuis

Apeldoorn · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1578

Rode Kruis Ziekenhuis

Beverwijk · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1579

Reinier de Graaf Ziekenhuis, locatie Delft

Delft · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1580

Deventer Ziekenhuis

Deventer · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1581

Slingeland Ziekenhuis

Doetinchem · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1582

Catharina Ziekenhuis

Eindhoven · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1583

Admiraal de Ruyter Ziekenhuis, locatie Goes

Goes · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1584

Groene Hart Ziekenhuis

Gouda · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1585

General Practitioners Research Institute (GPRI)

Groningen · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1586

Martini Ziekenhuis

Groningen · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1587

Spaarne Gasthuis, Haarlem Zuid

Haarlem · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1588

Saxenburgh Medisch Centrum

Hardenberg · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1589

Medische Centrum Leeuwarden

Leeuwarden · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1590

Radboudumc

Nijmegen · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1591

Ikazia Ziekenhuis

Rotterdam · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1592

Antonius Ziekenhuis, locatie D&A Research and Genetics

Sneek · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1593

Haga Ziekenhuis locatie Leyweg

The Hague · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1594

ETZ TweeSteden

Tilburg · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1595

Maxima Medisch Centrum, locatie Veldhoven

Veldhoven · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1596

Zaans Medisch Centrum

Zaandam · Netherlands

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1597

Specderm Poznanska sp.j.

Bialystok · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1598

NZOZ Centrum Medyczne KERmed

Bydgoszcz · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1599

Centrum Medyczne INTERCOR Sp. z o.o.

Bydgoszcz · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1600

Polsko-Amerykańskie Kliniki Serca PAKS Małopolskie Centrum Sercowo-Naczyniowe

Chrzanów · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1601

Polsko-Amerykańskie Kliniki Serca

Dąbrowa Górnicza · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1602

Centrum Kliniczno-Badawcze

Elblag · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1603

Uniwersyteckie Centrum Kliniczne

Gdansk · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1604

Przychodnie Grudziądz

Grudziądz · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1605

Polsko-Amerykańskie Kliniki Serca

Kędzierzyn-Koźle · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1606

Pro Salus Centrum Medyczne

Lodz · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1607

1 Wojskowy Szpital Kliniczny w Lublinie

Lublin · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1608

CenterMed Lublin NZOZ

Lublin · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1609

Wielospecjalistyczny Szpital Samodzielny Publiczny Zakład Opieki Zdrowotnej w Nowej Soli

Nowa Sól · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1610

Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu

Przemyśl · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1611

AKA-MED Centrum

Ruda Śląska · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1612

Polsko-Amerykańskie Kliniki Serca

Tychy · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1613

Clinical Best Solutions

Warsaw · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1614

Balsam Medica

Warsaw · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1615

Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś

Warsaw · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1616

NZOZ Centurm Medyczne SERAFIN-MED

Żarów · Poland

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1617

GCM Medical Group, PSC - Hato Rey Site

San Juan · Puerto Rico

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1618

CMI Cardiologie - Dr. Mercea Corina Delia

Baia Mare · Romania

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1619

CMI DNBM Dr. Pop Lavinia

Baia Mare · Romania

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1620

C.M.D.T.A. Neomed

Brasov · Romania

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1621

Centrul Medical Endocrinologie si Diabet Dr. Paveliu

Bucharest · Romania

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1622

Spitalul Clinic Județean de Urgență

Craiova · Romania

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1623

Centrul Medical Consultmed

Iași · Romania

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1624

Cardiomed Iași

Iași · Romania

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1625

Cardiomed

Târgu Mureş · Romania

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1626

Cliniq s.r.o.

Bratislava · Slovakia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1627

ENDIAMED s.r.o

Dolný Kubín · Slovakia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1628

JM-Interna s.r.o

Dolný Kubín · Slovakia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1629

IN-DIA

Lučenec · Slovakia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1630

NEDÚ - Národný endokrinologický a diabetologický ústav n.o.

Ľubochňa · Slovakia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1631

Sin Azucar

Malacky · Slovakia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1632

AMBORA s.r.o. Interna ambulancia

Martin · Slovakia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1633

Fakultná nemocnica Nitra

Nitra · Slovakia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1634

MEDIKALS

Piešťany · Slovakia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1635

MEDISPOL

Prešov · Slovakia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1636

ENRIN, s.r.o.

Rimavská Sobota · Slovakia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1637

Tatratrial s.r.o.

Rožňava · Slovakia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1638

Areteus s.r.o.

Trebišov · Slovakia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1639

MediPrax, s.r.o.

Trstená · Slovakia

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1640

The Catholic University of Korea, Bucheon St. Mary's Hospital

Bucheon-si · South Korea

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1641

Keimyung University Dongsan Hospital

Daegu · South Korea

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1642

Eulji University Hospital

Daejeon · South Korea

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1643

Boramae Medical Center

Dongjak-gu · South Korea

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1644

Chonnam National University Hospital

Gwangju · South Korea

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1645

Kyung Hee University Hospital

Seoul · South Korea

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1646

Seoul National University Hospital

Seoul · South Korea

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1647

Kyung Hee University Hospital at Gangdong

Seoul · South Korea

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1648

Sejong General Hospital

Sosa-gu · South Korea

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1649

Hospital Universitario Fundacion ALcorcon

Alcorcón · Spain

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1650

Hospital Germans Trias i Pujol

Badalona · Spain

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1651

Hospital de la Santa Creu i Sant Pau

Barcelona · Spain

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1652

Hospital de Denia Marina Salud

Denia · Spain

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1653

Hospital Clínico Universitario Virgen de la Arrixaca

El Palmar, Murcia · Spain

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1654

Hospital de Cabueñes

Gijón · Spain

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1655

Hospital Universitari de Girona Doctor Josep Trueta

Girona · Spain

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1656

Hospital Lucus Augusti

Lugo · Spain

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1657

Hospital Universitario La Paz

Madrid · Spain

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1658

Hospital Universitario Puerta de Hierro Majadahonda

Majadahonda · Spain

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1659

Hospital Universitario Quironsalud Madrid

Pozuelo de Alarcón · Spain

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1660

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca

Salamanca · Spain

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1661

Hospital de Sant Joan Despí Moisès Broggi

Sant Joan Despí · Spain

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1662

Hospital Arnau de Vilanova

Valencia · Spain

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1663

Changhua Christian Hospital

Changhua County · Taiwan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1664

Fu Jen Catholic University Hospital

New Taipei City · Taiwan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1665

Chung Shan Medical University Hospital

Taichung · Taiwan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1666

National Cheng Kung University Hospital

Tainan · Taiwan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1667

National Yang Ming Chiao Tung University Hospital

Yilan · Taiwan

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1668

Panthera Biopartners - Glasgow

Glasgow · United Kingdom

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1669

Hull Royal Infirmary

Hull · United Kingdom

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1670

Royal Free Hospital

London · United Kingdom

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1671

Royal Victoria Infirmary

Newcastle upon Tyne · United Kingdom

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1672

Salford Royal Hospital

Salford · United Kingdom

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1673

Torbay Hospital

Torquay · United Kingdom

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1674

Sunderland Royal Hospital

Tyne and Wear · United Kingdom

1 trial

Lepodisiran injection reduces heart attack and stroke risk in people with high lipoprotein(a).

Eli Lilly and CompanyPh 3NCT06292013 ↗

1675

Smiths Medical Center

Apache Junction · Arizona · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1676

Axsendo Clinical Research - Peak Heart & Vascular - Phoenix

Phoenix · Arizona · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1677

Southwest Kidney Institute - Surprise

Surprise · Arizona · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1678

John Muir Medical Center - Concord Campus

Concord · California · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1679

Ark Clinical Research - Fountain Valley

Fountain Valley · California · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1680

The Cardiovascular Center

Redding · California · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1681

Legacy Clinical Trials

Colorado Springs · Colorado · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1682

OptumCare Clinical Trials, LLC

Golden · Colorado · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3CompletedNCT07157774 ↗

1683

FWD Clinical Research

Boca Raton · Florida · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1684

American Research Institute

Cutler Bay · Florida · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1685

K2 Medical Research - Daytona Beach

Daytona Beach · Florida · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1686

Arrow Clinical Trials

Daytona Beach · Florida · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1687

Soffer Health Institute

Hollywood · Florida · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1688

K2 MEDICAL Research THE VILLAGES

Lady Lake · Florida · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1689

K2 Medical Research ORLANDO

Maitland · Florida · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1690

Dade Florida Clinical Research Center

Miami · Florida · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1691

Onhealth Research Center

Miami · Florida · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1692

Masters of Clinical Research

Augusta · Georgia · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1693

Elite Clinical Trials

Blackfoot · Idaho · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1694

Elite Clinical Trials

Rexburg · Idaho · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1695

AMR Clinical

Niles · Illinois · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1696

IU Health Bloomington

Bloomington · Indiana · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1697

Franciscan Physician Network - Indiana Heart Physicians

Indianapolis · Indiana · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1698

Saint Elizabeth Healthcare - Saint Elizabeth Covington Hospital

Covington · Kentucky · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1699

Tulane University School of Medicine

New Orleans · Louisiana · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1700

MaineHealth Cardiology

Scarborough · Maine · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1701

Metropolitan Cardiovascular Consultants

Beltsville · Maryland · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1702

Lucida Clinical Trials

New Bedford · Massachusetts · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1703

Boeson Research MSO

Missoula · Montana · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1704

Clinical Research of South Nevada

Las Vegas · Nevada · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1705

Renascor Clinical Research

Reno · Nevada · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1706

Vector Clinical Trials

Sparks · Nevada · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1707

Clinical Research of Philadelphia

Pennington · New Jersey · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1708

Southwest Cardiovascular Center

Albuquerque · New Mexico · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1709

Capital Cardiology Associates

Albany · New York · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1710

NYC Research

New York · New York · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1711

Weill Cornell Medical College

New York · New York · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1712

Rochester Clinical Research, LLC

Rochester · New York · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1713

SUNY Upstate Medical University

Syracuse · New York · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1714

Southgate Medical Group

West Seneca · New York · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1715

Velocity Clinical Research, Cincinnati, Mt. Auburn

Cincinnati · Ohio · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1716

Kaiser Permanente Sunnyside Medical Center

Clackamas · Oregon · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1717

Advanced Research Institute - Tigard

Tigard · Oregon · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1718

M3 Wake Research - Charleston

Charleston · South Carolina · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1719

Circle Clinical Research

Sioux Falls · South Dakota · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1720

WR-Clinsearch, LLC

Chattanooga · Tennessee · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1721

The Jackson Clinic

Jackson · Tennessee · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1722

St. David's Heart & Vascular PLLC dba Austin Heart

Austin · Texas · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1723

Dallas VA Medical Center

Dallas · Texas · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1724

Southwest Family Medicine Associates

Dallas · Texas · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1725

Renal Disease Research Institute

Dallas · Texas · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1726

IntraCare

Dallas · Texas · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1727

Cedar Health Research - Fort Worth

Fort Worth · Texas · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1728

GMG Clinical Research (DBA Radiance Clinical Research) - Lampasas

Lampasas · Texas · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1729

ERA Health Research-Texas

Midland · Texas · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1730

Ogden Clinic - Canyon View

Ogden · Utah · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1731

Advanced Research Institute

Ogden · Utah · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1732

Mary Washington Hospital

Fredericksburg · Virginia · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1733

Carient Heart & Vascular - Manassas

Manassas · Virginia · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1734

Manassas Clinical Research Center

Manassas · Virginia · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1735

TPMG (Tidewater Physicians Multispecialty Group) Clinical Research

Newport News · Virginia · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1736

York Clinical Research

Norfolk · Virginia · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1737

Reston Hospital Center

Reston · Virginia · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1738

Dominion Medical Associates, Inc.

Richmond · Virginia · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1739

ERA Health Research - CardioNow - Lynnwood

Lynnwood · Washington · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1740

Universal Research Group

Tacoma · Washington · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1741

Central Washington Health Services Association d/b/a Confluence Health

Wenatchee · Washington · United States

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1742

CEC - Consultorios de Especialidades Cardiovasculares

Bahía Blanca · Argentina

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1743

CONEXA Investigacion Clinica S.A.

Buenos Aires · Argentina

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1744

Kynet

Buenos Aires · Argentina

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1745

Cicemo Srl

Buenos Aires · Argentina

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1746

Cardiología Palermo

Buenos Aires · Argentina

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1747

Mautalen Salud e Investigación

Buenos Aires · Argentina

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1748

CEMEDIAB

C.a.b.a. · Argentina

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1749

Centro Medico Privado San Vicente Diabetes

Córdoba · Argentina

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1750

CMD-Centro Médico y Diagnóstico por Imágenes

Junín · Argentina

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1751

Polo de Salud Vistalba

Lujan de Cuyo · Argentina

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1752

Fundacion Scherbovsky

Mendoza · Argentina

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1753

Centro Rosarino de Investigaciones Clinicas (CRICs)

Rosario · Argentina

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1754

Santa Maria de la Salud Centro Medico

San Isidro · Argentina

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1755

Centro de Salud e Investigaciones Médicas

Santa Rosa · Argentina

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1756

Centro de Investigaciones Medicas Temperley

Temperley · Argentina

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1757

Instituto de Investigaciones Clinicas Zarate

Zárate · Argentina

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1758

Nightingale Research - Frankston

Frankston · Australia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1759

Royal Hobart Hospital

Hobart · Australia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1760

Ipswich Hospital

Ipswich · Australia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1761

Sydney Cardiometabolic Centre

Liverpool · Australia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1762

Maroochy Private Hospital

Maroochydore · Australia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1763

Advara HeartCare - Milton

Milton · Australia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1764

Southern Adelaide Diabetes & Endocrine Services

Oaklands Park · Australia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1765

Regional Research Institute

Toowoomba · Australia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1766

Latrobe Regional Health

Traralgon · Australia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1767

Medizinische Universität Graz

Graz · Austria

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1768

Cardio Metabolic Centre

Mattersburg · Austria

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1769

imed St. Pölten

Sankt Pölten · Austria

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1770

Imed19-privat

Vienna · Austria

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1771

AZORG Campus Aalst-Moorselbaan

Aalst · Belgium

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1772

ANIMA Research

Alken · Belgium

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1773

AZ Sint-Jan Brugge-Oostende AV

Bruges · Belgium

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1774

Jan Yperman Ziekenhuis

Ieper · Belgium

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1775

Kormont

Kluisbergen · Belgium

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1776

Clinical Chc Montlégia

Liège · Belgium

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1777

InoKura

Liège · Belgium

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1778

Gezondheidshuis De Gloed

Machelen · Belgium

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1779

Meclinas

Mechelen · Belgium

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1780

Pneumocare

Namur · Belgium

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1781

Artsen Netwerk De Schelde

Oudenaarde · Belgium

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1782

Artsenpraktijk OHIO

Oudenaarde · Belgium

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1783

Private Practice - Dr. De Watertoren

Tielt · Belgium

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1784

Private Practice - Dr. Tim Decraecke (Zwalm)

Zwalm · Belgium

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1785

Hospital Sirio Libanes

Brasília · Brazil

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1786

Hospital do Coração do Brasil

Brasília · Brazil

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1787

Instituto de Ensino e Pesquisa Clinica do Ceara

Fortaleza · Brazil

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1788

C-MEP - Centro Multidisciplinar de Ensino e Pesquisa

Joinville · Brazil

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1789

CPHOSP Manaus Medicina, Ensino e Pesquisa

Manaus · Brazil

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1790

Instituto Atena de Pesquisa Clinica

Natal · Brazil

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1791

Hospital Maternidade E Pronto Socorro Santa Lucia

Poços de Caldas · Brazil

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1792

Irmandade da Santa Casa de Misericórdia de Porto Alegre

Porto Alegre · Brazil

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1793

Rede AME SAÚDE

Recife · Brazil

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1794

Centro de Pesquisa Silvestre Santé

Rio Branco · Brazil

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1795

Inovace Pesquisa Clínica

Salvador · Brazil

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1796

Riverside Cardiology and Diagnostic Imaging

Etobicoke · Canada

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1797

Winterberry Research Inc.

Hamilton · Canada

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1798

Institut de Cardiologie de Montreal

Montreal · Canada

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1799

IUCPQ

Québec · Canada

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1800

Bluewater Clinical Research Group Inc.

Sarnia · Canada

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1801

KMH Cardiology Centres - Stoney Creek

Stoney Creek · Canada

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1802

Unity Health Toronto, St. Michael's Hospital

Toronto · Canada

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1803

Fadia El Boreky Medicine

Waterloo · Canada

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1804

Clinical Research Solutions - Kitchener

Waterloo · Canada

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1805

Xuanwu Hospital Capital Medical University

Beijing · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1806

Beijing Pinggu District Hospital

Beijing · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1807

Xiangya Hospital Central South University

Changsha · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1808

The First People's Hospital of Changzhou

Changzhou · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1809

Daqing People's Hospital

Daqing · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1810

The First People's Hospital of Foshan

Foshan · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1811

Zhujiang Hospital

Guangzhou · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1812

Zhejiang Hospital

Hangzhou · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1813

Jining No.1 People's Hospital

Jining · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1814

Huaihe Hospital of Henan University

Kaifeng · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1815

The First Affiliated Hospital of Henan University of Science &Technology

Luoyang Shi · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1816

Affiliated Hospital of Luzhou Medical College

Luzhou · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1817

Nanchang People's Hospital

Nanchang · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1818

Jiangxi Provincial People's Hospital

Nanchang · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1819

Zhongda Hospital Southeast University

Nanjing · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1820

Jiangsu Province Hospital

Nanjing · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1821

The first affiliated hospital of Ningbo university

Ningbo · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1822

Shanghai Xuhui Central Hospital

Shanghai · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1823

The First Affiliated Hospital of Shantou University Medical College

Shantou · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1824

The Second Affiliated Hospital of Soochow University

Suzhou · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1825

The 2nd Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

Wenzhou · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1826

Xuzhou Central Hospital

Xuzhou · China

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1827

Kardiologie Stříbrný

Brno · Czechia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1828

MUDr. Karel Kamenik - Kardiologicka Ambulance

Brno · Czechia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1829

Kardio Chlumec

Chlumec nad Cidlinou · Czechia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1830

INTENDIA klinika s.r.o.

Chrudim III · Czechia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1831

DR. HAUS - Kardiologicka Ambulance

Český Krumlov · Czechia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1832

DIKa Centrum

Havířov · Czechia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1833

CTC Hodonin s.r.o.

Hodonín · Czechia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1834

Fakultni nemocnice Hradec Kralove

Hradec Králové · Czechia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1835

Cévní ambulance Nový Jičín

Nový Jičín · Czechia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1836

MUDr. Buchta s.r.o., Kardiologicka ambulance

Ostrava · Czechia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1837

Pratia Pardubice a.s.

Pardubice · Czechia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1838

Diabet2 s.r.o., diabetologicka a interni ambulance

Prague · Czechia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1839

Clinoxus

Prague · Czechia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1840

Centre Hospitalier d'Annecy

Epagny Metz-Tessy · France

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1841

Chu Grenoble Alpes

La Tronche · France

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1842

Centre Hospitalier Universitaire de Poitiers

Poitiers · France

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1843

Centre Hospitalier Universitaire de Saint Étienne - Hôpital Nord

Saint-Priest-en-Jarez · France

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1844

Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau

Tours · France

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1845

Klinische Forschung Berlin-Mitte

Berlin · Germany

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1846

FutureMeds GmbH

Berlin · Germany

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1847

Klinische Forschung Dresden

Dresden · Germany

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1848

Zentrum für klinische Prüfungen in der Facharztzentrum Dresden-Neustadt Betriebsgesellschaft mbH

Dresden · Germany

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1849

Unterfrintroper Hausarztzentrum Klinische Forschung

Essen · Germany

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1850

ClinPhenomics CVC GmbH

Frankfurt · Germany

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1851

Universitaetsklinikum Freiburg

Freiburg im Breisgau · Germany

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1852

Universitätsmedizin Greifswald

Greifswald · Germany

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1853

HRF II - Hamburger Rheuma Forschungszentrum II MVZ für Rheumatologie und Autoimmunmedizin Hamburg GmbH / -T

Hamburg · Germany

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1854

Velocity Clinical Research, Hamburg

Hamburg · Germany

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1855

Klinische Forschung Hamburg

Hamburg · Germany

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1856

Klinische Forschung Hannover-Mitte

Hanover · Germany

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1857

Klinische Forschung Karlsruhe

Karlsruhe · Germany

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1858

Universität zu Lübeck - Institut für Endokrinologie und Diabetes

Lübeck · Germany

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1859

Dedicated Research Site FutureMeds

Offenbach · Germany

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1860

RED-Institut GmbH

Oldenburg · Germany

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1861

Klinische forschung Schwerin GmbH

Schwerin · Germany

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1862

Evangelisches Krankenhaus Witten

Witten · Germany

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1863

Evangelismos General Hospital of Athens

Athens · Greece

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1864

Athens Medical Center - Psychikon branch

Athens · Greece

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1865

General Hospital of Nikaia-Piraeus "Agios Panteleimon"

Nikaia Piraeus · Greece

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1866

University Hospital of Patras

Pátrai · Greece

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1867

G. Gennimatas General Hospital of Thessaloniki

Thessaloniki · Greece

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1868

Euromedica General Clinic of Thessaloniki

Thessaloniki · Greece

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1869

Ippokrateio General Hospital of Thessaloniki

Thessaloniki · Greece

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1870

European Interbalkan Medical Center

Thessaloniki · Greece

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1871

Semmelweis Egyetem

Budapest · Hungary

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1872

Gottsegen György Országos Kardiovaszkuláris Intézet

Budapest · Hungary

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1873

Cardiogeneral Egészségügyi Kft.

Budapest · Hungary

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1874

Arina Trial Research

Orosháza · Hungary

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1875

CoroMed

Pécs · Hungary

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1876

KomplexLabor Diagnosztika

Szeged · Hungary

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1877

Belagavi Institute of Medical Sciences - Belagavi

Belgavi · India

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1878

Eternal Heart Care Center and Research Institute

Jaipur · India

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1879

Sanjay Gandhi Post Graduate Institute of Medical Sciences

Lucknow · India

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1880

Kingsway Hospitals (Best Multispeciality Hospital in Nagpur)

Nagpur · India

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1881

Sir Ganga Ram Hospital

New Delhi · India

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1882

Ashirwad Hospital and Research Centre

Ulhasnagar · India

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1883

Azienda Ospedaliera di Caserta Sant' Anna e San Sebastiano

Caserta · Italy

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1884

Azienda Ospedaliero Universitaria S.Anna

Ferrara (Cona) · Italy

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1885

A.O.U. Policlinico Paolo Giaccone

Palermo · Italy

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1886

Fondazione IRCCS Policlinico San Matteo

Pavia · Italy

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1887

Azienda Ospedaliera Sant'Andrea

Rome · Italy

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1888

Akita University Hospital

Akita · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1889

Yamasaki Family Clinic

Amagasaki · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1890

Institute of Science Tokyo Hospital

Bunkyō · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1891

Shonan Fujisawa Tokushukai Hospital

Fujisawa · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1892

Tenjin Sogo Clinic

Fukuoka · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1893

Hamanomachi Hospital

Fukuoka · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1894

Fukuoka University Hospital

Fukuoka · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1895

Kyushu Central Hospital

Fukuoka · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1896

Gifu University Hospital

Gifu · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1897

Hachioji Diabetes Clinic

Hachioji-shi · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1898

Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital

Hiroshima · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1899

Hiroshima Prefectural Hospital

Hiroshima · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1900

National Kohnodai Medical Center

Ichikawa · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1901

Nippon Medical School Chiba Hokusoh Hospital

Inzai · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1902

Nihon University Itabashi Hospital

Itabashiku · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1903

Shimane University Hospital

Izumo · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1904

Shonan Kamakura General Hospital

Kamakura · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1905

Mizonokuchi Okamoto Clinic

Kawasaki · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1906

Teikyo University Mizonokuchi Hospital

Kawasaki · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1907

Kobe University Hospital

Kobe · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1908

Yoshimura Clinic

Kumamoto · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1909

Omi Medical Center

Kusatsu · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1910

Toho University Ohashi Medical Center

Meguro-ku · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1911

Yokoi Clinic

Minoh · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1912

Nakamoto Internal Medicine Clinic

Mito · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1913

MinamiAkatsukaClinic

Mito · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1914

Nagasaki Harbor Medical Center

Nagasaki · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1915

Japan Public Health Association

Nagoya · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1916

Nakakinen clinic

Naka · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1917

Nishiyamadou Keiwa Hospital

Naka · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1918

International University of Health and Welfare Narita Hospital

Narita · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1919

Shimamura Memorial Hospital

Nerima-ku · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1920

Okayama Rosai Hospital

Okayama · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1921

Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai

Osaka · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1922

Osaka Metropolitan University Hospital

Osaka · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1923

Minamiosaka Hospital

Osaka · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1924

Abe Clinic

Ōita · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1925

Sato Hospital - Osaki

Ōsaki · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1926

Toho University Omori Medical Center

Ōta-ku · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1927

Medical Corporation Koshinkai - Thyroid and Diabetes Clinic Nakanoshima

Sapporo · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1928

Cardiovascular Hospital Of Central Japan - Kitakanto Cardiovascular Hospital

Shibukawa · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1929

Clinical Research Hospital Tokyo

Shinjuku-ku · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1930

Tokyo Asbo Clinic

Tokyo · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1931

Medical Corporation Yuga Tsuruma Kaneshiro Diabetes Clinic

Yamato-shi · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1932

SHOWA Medical University Fujigaoka Hospital

Yokohama · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1933

Yokohama Minami Kyosai Hospital

Yokohama · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1934

Yokosuka City General Medical Center

Yokosuka · Japan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1935

Centro de Atencion al Diabetico Actopan

Actopan · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1936

Medical Center Metas

Chihuahua City · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1937

Centro de Estudios de Investigacion Metabolicos y Cardiovasculares, S.C.

Ciudad Madero · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1938

Centro de Investigación Clínica y Medicina Traslacional (CIMeT)

Guadalajara · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1939

Diseno y Planeacion en Investigacion Medica - Guadalajara - Calle Amado Nervo

Guadalajara · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1940

Instituto Jalisciense de Metabolismo

Guadalajara · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1941

Private Practice - Dr. Arechavaleta Granell Maria del Rosario

Guadalajara · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1942

Salud Cardiovascular

Guadalajara · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1943

Hermosillo Heart Team - Sinacor Hermosillo

Hermosillo · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1944

Accelerium Clinical Research

Mazatlán · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1945

Centro Médico Lic. Arturo Montiel Rojas ISSEMYM

Metepec · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1946

Centro de Investigacion en Artritis y Osteoporosis SC

Mexicali · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1947

RM Pharma Specialists - Unidad Especializada en Datos

Mexico City · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1948

Centro de Investigación Clinica Chapultepec

Mexico City · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1949

Private Practice - Dr. Eduardo Julián José Roberto Chuquiure Valenzuela

Mexico City · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1950

Instituto Nacional de Cardiologia Ignacio Chavez

Mexico City · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1951

Centro de Desarrollo Biomedico

Mérida · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1952

Kohler & Milstein Research S.A. De C.V.

Mérida · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1953

Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares

México · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1954

CEINV Salud

Monterrey · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1955

IMED Internal Medicine Clin Trials

Monterrey · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1956

Clinica de Enfermedades Cronicas y Procedimientos Especiales, SC

Morelia · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1957

Fundación Santos y de la Garza Evía I.B.P

San Pedro Garza García · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1958

Scientia Investigación Clínica TJ

Tijuana · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1959

Arké SMO S.A de C.V

Veracruz · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1960

FAICIC S. de R.L. de C.V.

Veracruz · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1961

Integradora Multidisciplinaria Del Grijalva - Sinacor Villahermosa

Villahermosa · Mexico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1962

Noordwest Ziekenhuisgroep

Alkmaar · Netherlands

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1963

EB Medical Research

Almere Stad · Netherlands

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1964

OLVG Oost

Amsterdam · Netherlands

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1965

Ziekenhuis Rijnstate

Arnhem · Netherlands

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1966

PT&R / PreCare Trial & Recruitment

Born · Netherlands

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1967

Ziekenhuis Bethesda

Hoogeveen · Netherlands

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1968

Canisius-Wilhelmina Ziekenhuis

Nijmegen · Netherlands

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1969

Albert Schweitzer Ziekenhuis, locatie Zwijndrecht

Zwijndrecht · Netherlands

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1970

Pro&Diagnostic

Bielsko-Biala · Poland

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1971

Centrum Medyczne "Hipokrates" S.C. Elżbieta I Grzegorz Grześk

Bydgoszcz · Poland

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1972

Euromedica

Grudziądz · Poland

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1973

Gyncentrum sp. z o.o. NZOZ Holsamed - oddział Libero

Katowice · Poland

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1974

Centrum Medyczne Komorniki

Komorniki · Poland

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1975

FutureMeds - Lodz

Lodz · Poland

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1976

Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie

Lublin · Poland

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1977

IRMED

Piotrkow Trybunalski · Poland

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1978

Futuremeds Targowek

Warsaw · Poland

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1979

Przychodnia FutureMeds Wrocław

Wroclaw · Poland

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1980

Puerto Rico Health and Wellness Institute

Dorado · Puerto Rico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1981

Isis Clinical Research Center

Guaynabo · Puerto Rico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1982

Investigadores del Este

Humacao · Puerto Rico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1983

Research and Cardiovascular Corp.

Ponce · Puerto Rico

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1984

Cardioplus Center SRL

Baia Mare · Romania

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1985

Spitalul Clinic De Urgenta Prof Dr Agrippa Ionescu

Baloteşti · Romania

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1986

Centrul Medical Unirea

Brasov · Romania

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1987

Delta Health Care

Bucharest · Romania

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1988

The National Institute of Diabetes, Nutrition and Metabolic Diseases "Prof. Dr. N. Paulescu"

Bucharest · Romania

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1989

Spitalul Clinic Profesor Doctor Theodor Burghele

Bucharest · Romania

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1990

Diabet Med

Bucharest · Romania

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1991

Milena Sante

Galați · Romania

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1992

Medical Practice SRL

Oradea · Romania

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1993

Spital Clinic Judetean de Urgenta Tg.Mures

Tg.Mures · Romania

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1994

National University Heart Centre, Singapore

Singapore · Singapore

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1995

National Heart Centre Singapore

Singapore · Singapore

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1996

Tan Tock Seng Hospital

Singapore · Singapore

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1997

Changi General Hospital

Singapore · Singapore

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗

1998

PreMedix

Bratislava · Slovakia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

1999

Ambulancia diabetológie a porúch látkovej premeny a výživy - DIABEDA

Bratislava · Slovakia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2000

Narodny ustav srdcovych a cievnych chorob

Bratislava · Slovakia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2001

Nemocnica s poliklinikou Dunajska Streda, a.s.

Dunajská Streda · Slovakia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2002

Nemocnica s poliklinikou Sv. Lukasa Galanta, a. s.

Galanta · Slovakia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2003

Cardio D&R

Košice · Slovakia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2004

MediVet s.r.o.

Malacky · Slovakia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2005

Nemocnica Malacky

Malacky · Slovakia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2006

Nemocnica s poliklinikou Stefana Kukuru Michalovce a.s.

Michalovce · Slovakia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2007

BENIMED s.r.o. Kardiologicka ambulancia

Piešťany · Slovakia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2008

Vseobecna nemocnica Rimavska Sobota

Rimavská Sobota · Slovakia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2009

Nemocnica s poliklinikou Spišská Nová Ves

Spišská Nová Ves · Slovakia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2010

Vranovska Nemocnica

Vranov nad Topľou · Slovakia

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2011

Chosun University Hospital

Gwangju · South Korea

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2012

Hospital San Rafael - La Coruña

A Coruña · Spain

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2013

Hospital Universitari Vall d'Hebron

Barcelona · Spain

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2014

EAP Osona Sud - Alt Congost S.L.P

Centelles · Spain

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2015

Hospital Universitario de Gran Canaria Doctor Negrín

Las Palmas de Gran Canaria · Spain

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2016

Complejo Asistencial Universitario de León - Hospital de León

León · Spain

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2017

Complejo Hospitalario Ruber Juan Bravo

Madrid · Spain

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2018

Hospital La Princesa

Madrid · Spain

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2019

Hospital Universitario Infanta Leonor

Madrid · Spain

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2020

Hospital Quirón Málaga

Málaga · Spain

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2021

H.R.U Málaga - Hospital General

Málaga · Spain

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2022

CHOP - Hospital Universitario Montecelo

Pontevedra · Spain

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2023

Centro de Salud San Juan de la Cruz

Pozuelo de Alarcón · Spain

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2024

Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)

Seville · Spain

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2025

Hospital Quiron Infanta Luisa

Seville · Spain

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2026

Hospital Universitario de Toledo

Toledo · Spain

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2027

Hospital Vithas Valencia 9 de octubre

Valencia · Spain

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2028

Hospital Universitario Rio Hortega

Valladolid · Spain

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2029

National Cheng-Kung Uni. Hosp.

Tainan · Taiwan

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2030

South Eastern Health and Social Care Trust

Belfast · United Kingdom

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2031

Glan Clwyd Hospital

Bodelwyddan · United Kingdom

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2032

Bradford on Avon Health Centre

Bradford-on-Avon · United Kingdom

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2033

FutureMeds Glasgow - CPS Research

Glasgow · United Kingdom

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2034

Velocity Clinical Research, High Wycombe

High Wycombe · United Kingdom

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2035

HMC Health Group - Meadows Centre for Health

Hounslow · United Kingdom

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2036

Raigmore Hospital

Inverness · United Kingdom

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2037

Oak Tree Surgery

Liskeard · United Kingdom

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2038

FutureMeds - London

London · United Kingdom

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2039

The Adam Practice

Poole · United Kingdom

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2040

Rame Group Practice

Torpoint · United Kingdom

1 trial

Muvalaplin reduces cardiovascular events in adults with elevated lipoprotein(a) and heart disease.

Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗

2041

Advanced Cardiovascular - Alexander City ( Site 0158)

Alexander City · Alabama · United States

1 trial

MK-7262 combined with enlicitide lowers lipoprotein(a) and LDL cholesterol in high-risk patients.

Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗

2042

AMR Clinical Mobile ( Site 0149)

Mobile · Alabama · United States

1 trial

MK-7262 combined with enlicitide lowers lipoprotein(a) and LDL cholesterol in high-risk patients.

Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗

2043

National Heart Institute ( Site 0113)

Beverly Hills · California · United States

1 trial

MK-7262 combined with enlicitide lowers lipoprotein(a) and LDL cholesterol in high-risk patients.

Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗

2044

Clinical Trials Research ( Site 0127)

Lincoln · California · United States

1 trial

MK-7262 combined with enlicitide lowers lipoprotein(a) and LDL cholesterol in high-risk patients.

Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗

2045

Chase Medical Research, LLC ( Site 0163)

Waterbury · Connecticut · United States

1 trial

MK-7262 combined with enlicitide lowers lipoprotein(a) and LDL cholesterol in high-risk patients.

Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗

2046

Inpatient Research Clinic ( Site 0110)

Miami Lakes · Florida · United States

1 trial

MK-7262 combined with enlicitide lowers lipoprotein(a) and LDL cholesterol in high-risk patients.

Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗

2047

Clinical Research Trials of Florida ( Site 0101)

Tampa · Florida · United States

1 trial

MK-7262 combined with enlicitide lowers lipoprotein(a) and LDL cholesterol in high-risk patients.

Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗

2048

Conquest Research LLC ( Site 0140)

Winter Park · Florida · United States

1 trial

MK-7262 combined with enlicitide lowers lipoprotein(a) and LDL cholesterol in high-risk patients.

Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗

2049

New Mexico Clinical Research & Osteoporosis Center ( Site 0119)

Albuquerque · New Mexico · United States

1 trial

MK-7262 combined with enlicitide lowers lipoprotein(a) and LDL cholesterol in high-risk patients.

Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗

2050

Remington-Davis, Inc. ( Site 0107)

Columbus · Ohio · United States

1 trial

MK-7262 combined with enlicitide lowers lipoprotein(a) and LDL cholesterol in high-risk patients.

Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗

2051

Holston Medical Group ( Site 0117)

Kingsport · Tennessee · United States

1 trial

MK-7262 combined with enlicitide lowers lipoprotein(a) and LDL cholesterol in high-risk patients.

Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗

2052

Carient Heart & Vascular - Manassas ( Site 0165)

Manassas · Virginia · United States

1 trial

MK-7262 combined with enlicitide lowers lipoprotein(a) and LDL cholesterol in high-risk patients.

Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗

2053

Allina Health

Minneapolis · Minnesota · United States

1 trial

Doctor and patient education improves cholesterol testing and treatment after hospitalization for heart events.

Duke UniversityRecruitingNCT06471036 ↗

2054

Research Site

Miami Lakes · Florida · United States

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2055

Research Site

Las Vegas · Nevada · United States

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2056

Research Site

New York · New York · United States

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2057

Research Site

Cincinnati · Ohio · United States

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2058

Research Site

Chattanooga · Tennessee · United States

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2059

Research Site

Kingwood · Texas · United States

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2060

Research Site

McAllen · Texas · United States

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2061

Research Site

São Caetano do Sul · Brazil

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2062

Research Site

London · Ontario · Canada

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2063

Research Site

Trois-Rivières · Quebec · Canada

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2064

Research Site

Hradec Králové · Czechia

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2065

Research Site

Aarhus N · Denmark

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2066

Research Site

Copenhagen · Denmark

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2067

Research Site

Esbjerg · Denmark

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2068

Research Site

Herlev · Denmark

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2069

Research Site

Herning · Denmark

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2070

Research Site

Hvidovre · Denmark

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2071

Research Site

Viborg · Denmark

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2072

Research Site

Helsinki · Finland

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2073

Research Site

Kuopio · Finland

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2074

Research Site

Tampere · Finland

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2075

Research Site

Turku · Finland

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2076

Research Site

Bron · France

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2077

Research Site

Dijon · France

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2078

Research Site

Marseille · France

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2079

Research Site

Paris · France

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2080

Research Site

Saint-Herblain · France

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2081

Research Site

Fukushima · Japan

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2082

Research Site

Kita-gun · Japan

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2083

Research Site

Suita-shi · Japan

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2084

Research Site

Takatsuki-shi · Japan

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2085

Research Site

Amsterdam · Netherlands

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2086

Research Site

Roosendaal · Netherlands

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2087

Research Site

Rotterdam · Netherlands

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2088

Research Site

Utrecht · Netherlands

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2089

Research Site

Christchurch · New Zealand

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2090

Research Site

Grafton · New Zealand

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2091

Research Site

Bodø · Norway

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2092

Research Site

Grålum · Norway

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2093

Research Site

Oslo · Norway

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2094

Research Site

Trondheim · Norway

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2095

Research Site

Nitra · Slovakia

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2096

Research Site

Žilina · Slovakia

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2097

Research Site

Gyeonggi-do · South Korea

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2098

Research Site

Reus · Spain

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2099

Research Site

Gothenburg · Sweden

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2100

Research Site

Linköping · Sweden

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2101

Research Site

Lund · Sweden

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2102

Research Site

Stockholm · Sweden

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2103

Research Site

Uppsala · Sweden

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2104

Research Site

İzmit · Turkey (Türkiye)

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2105

Research Site

Hồ Chí Minh · Vietnam

1 trial

AZD0780 lowers LDL cholesterol in adults with inherited high cholesterol and heart disease.

AstraZenecaPh 3NCT07000136 ↗

2106

Research Site

Huntsville · Alabama · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2107

Research Site

Irondale · Alabama · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2108

Research Site

Mobile · Alabama · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2109

Research Site

Gilbert · Arizona · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2110

Research Site

Phoenix · Arizona · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2111

Research Site

Sun City West · Arizona · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2112

Research Site

Gardena · California · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2113

Research Site

Lancaster · California · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2114

Research Site

Lincoln · California · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2115

Research Site

Torrance · California · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2116

Research Site

West Hills · California · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2117

Research Site

Hamden · Connecticut · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2118

Research Site

Boca Raton · Florida · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2119

Research Site

Hallandale · Florida · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2120

Research Site

Hialeah · Florida · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2121

Research Site

Miami · Florida · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2122

Research Site

New Port Richey · Florida · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2123

Research Site

Pembroke Pines · Florida · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2124

Research Site

Seminole · Florida · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2125

Research Site

Tampa · Florida · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2126

Research Site

Atlanta · Georgia · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2127

Research Site

Decatur · Georgia · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2128

Research Site

Winfield · Illinois · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2129

Research Site

Evansville · Indiana · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2130

Research Site

Indianapolis · Indiana · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2131

Research Site

Ames · Iowa · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2132

Research Site

El Dorado · Kansas · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2133

Research Site

Wichita · Kansas · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2134

Research Site

Owensboro · Kentucky · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2135

Research Site

Kenner · Louisiana · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2136

Research Site

Lafayette · Louisiana · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2137

Research Site

Lake Charles · Louisiana · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2138

Research Site

Shreveport · Louisiana · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2139

Research Site

Zachary · Louisiana · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2140

Research Site

Annapolis · Maryland · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2141

Research Site

Baltimore · Maryland · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2142

Research Site

Beltsville · Maryland · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2143

Research Site

Potomac · Maryland · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2144

Research Site

Chesterfield · Missouri · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2145

Research Site

Jefferson City · Missouri · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2146

Research Site

Kansas City · Missouri · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2147

Research Site

Missoula · Montana · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2148

Research Site

Buffalo · New York · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2149

Research Site

Rochester · New York · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2150

Research Site

The Bronx · New York · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2151

Research Site

Durham · North Carolina · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2152

Research Site

Greensboro · North Carolina · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2153

Research Site

Hickory · North Carolina · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2154

Research Site

New Bern · North Carolina · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2155

Research Site

Raleigh · North Carolina · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2156

Research Site

Rocky Mount · North Carolina · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2157

Research Site

Salisbury · North Carolina · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2158

Research Site

Statesville · North Carolina · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2159

Research Site

Wilmington · North Carolina · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2160

Research Site

Fargo · North Dakota · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2161

Research Site

Blue Ash · Ohio · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2162

Research Site

Columbus · Ohio · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2163

Research Site

Camp Hill · Pennsylvania · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2164

Research Site

Horsham · Pennsylvania · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2165

Research Site

Philadelphia · Pennsylvania · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2166

Research Site

West Chester · Pennsylvania · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2167

Research Site

Anderson · South Carolina · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2168

Research Site

Fort Mill · South Carolina · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2169

Research Site

Mauldin · South Carolina · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2170

Research Site

Mt. Pleasant · South Carolina · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2171

Research Site

North Charleston · South Carolina · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2172

Research Site

Rapid City · South Dakota · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2173

Research Site

Bristol · Tennessee · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2174

Research Site

Knoxville · Tennessee · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2175

Research Site

Beaumont · Texas · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2176

Research Site

El Paso · Texas · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2177

Research Site

Irving · Texas · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2178

Research Site

Katy · Texas · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2179

Research Site

Paris · Texas · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2180

Research Site

San Marcos · Texas · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2181

Research Site

Sugar Land · Texas · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2182

Research Site

Charlottesville · Virginia · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2183

Research Site

Hampton · Virginia · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2184

Research Site

Norfolk · Virginia · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2185

Research Site

Suffolk · Virginia · United States

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2186

Research Site

Córdoba · Argentina

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2187

Research Site

Godoy Cruz · Argentina

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2188

Research Site

San Nicolás · Argentina

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2189

Research Site

San Vicente · Argentina

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2190

Research Site

Zárate · Argentina

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2191

Research Site

Coffs Harbour · Australia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2192

Research Site

Ipswich · Australia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2193

Research Site

Joondalup · Australia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2194

Research Site

Leabrook · Australia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2195

Research Site

Liverpool · Australia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2196

Research Site

Maroubra · Australia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2197

Research Site

Woolloongabba · Australia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2198

Research Site

Brasília · Brazil

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2199

Research Site

Campina Grande do Sul · Brazil

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2200

Research Site

Goiânia · Brazil

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2201

Research Site

Porto Alegre · Brazil

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2202

Research Site

Rio de Janeiro · Brazil

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2203

Research Site

Dupnitsa · Bulgaria

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2204

Research Site

Haskovo · Bulgaria

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2205

Research Site

Sliven · Bulgaria

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2206

Research Site

Varna · Bulgaria

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2207

Research Site

Surrey · British Columbia · Canada

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2208

Research Site

Cambridge · Ontario · Canada

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2209

Research Site

Courtice · Ontario · Canada

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2210

Research Site

Guelph · Ontario · Canada

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2211

Research Site

Hamilton · Ontario · Canada

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2212

Research Site

Mississauga · Ontario · Canada

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2213

Research Site

North York · Ontario · Canada

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2214

Research Site

Sarnia · Ontario · Canada

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2215

Research Site

Stoney Creek · Ontario · Canada

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2216

Research Site

Stouffville · Ontario · Canada

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2217

Research Site

Toronto · Ontario · Canada

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2218

Research Site

Joliette · Quebec · Canada

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2219

Research Site

Sherbrooke · Quebec · Canada

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2220

Research Site

Independencia · Chile

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2221

Research Site

Victoria · Chile

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2222

Research Site

Benešov · Czechia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2223

Research Site

Brandýs nad Labem · Czechia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2224

Research Site

Chlumec nad Cidlinou · Czechia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2225

Research Site

České Budějovice · Czechia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2226

Research Site

Hodonín · Czechia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2227

Research Site

Jílové u Prahy · Czechia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2228

Research Site

Klatovy · Czechia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2229

Research Site

Praha Uhříněves · Czechia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2230

Research Site

Příbram · Czechia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2231

Research Site

Tábor · Czechia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2232

Research Site

Teplice · Czechia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2233

Research Site

Trutnov · Czechia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2234

Research Site

Amberg · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2235

Research Site

Bad Homburg · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2236

Research Site

Essen · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2237

Research Site

Falkensee · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2238

Research Site

Frankfurt · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2239

Research Site

Freiburg im Breisgau · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2240

Research Site

Greifswald · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2241

Research Site

Hamburg · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2242

Research Site

Hanover · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2243

Research Site

Heidelberg · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2244

Research Site

Hohenmölsen · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2245

Research Site

Kaiserslautern · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2246

Research Site

Karlsruhe · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2247

Research Site

Kiel · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2248

Research Site

Magdeburg · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2249

Research Site

Mannheim · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2250

Research Site

Markkleeberg · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2251

Research Site

Munich · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2252

Research Site

München · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2253

Research Site

Münster · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2254

Research Site

Nuremberg · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2255

Research Site

Offenbach · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2256

Research Site

Potsdam · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2257

Research Site

Schwerin · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2258

Research Site

Stuhr · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2259

Research Site

Stuttgart · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2260

Research Site

Wermsdorf · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2261

Research Site

Witten · Germany

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2262

Research Site

Balatonfüred · Hungary

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2263

Research Site

Békéscsaba · Hungary

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2264

Research Site

Dunaújváros · Hungary

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2265

Research Site

Kalocsa · Hungary

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2266

Research Site

Kaposvár · Hungary

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2267

Research Site

Nyíregyháza-Sóstóhegy · Hungary

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2268

Research Site

Orosháza · Hungary

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2269

Research Site

Pécs · Hungary

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2270

Research Site

Szeged · Hungary

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2271

Research Site

Zalaegerszeg · Hungary

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2272

Research Site

Belagavi · India

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2273

Research Site

Dehradun · India

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2274

Research Site

Kanpur · India

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2275

Research Site

Kochi · India

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2276

Research Site

New Delhi · India

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2277

Research Site

Ami-machi · Japan

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2278

Research Site

Asahi-shi · Japan

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2279

Research Site

Kasuya-gun · Japan

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2280

Research Site

Kitakyushu · Japan

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2281

Research Site

Kure-shi · Japan

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2282

Research Site

Nagoya · Japan

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2283

Research Site

Suwa-shi · Japan

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2284

Research Site

Tsukuba · Japan

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2285

Research Site

Ushiku-shi · Japan

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2286

Research Site

Utsunomiya · Japan

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2287

Research Site

Bandar Aman Jaya · Malaysia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2288

Research Site

Ipoh · Malaysia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2289

Research Site

Kuching · Malaysia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2290

Research Site

Sarawak Miri · Malaysia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2291

Research Site

Seri Manjung · Malaysia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2292

Research Site

Sibu · Malaysia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2293

Research Site

Sungai Buloh · Malaysia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2294

Research Site

Bialystok · Poland

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2295

Research Site

Gdansk · Poland

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2296

Research Site

Gdynia · Poland

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2297

Research Site

Katowice · Poland

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2298

Research Site

Kędzierzyn-Koźle · Poland

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2299

Research Site

Krakow · Poland

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2300

Research Site

Lodz · Poland

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2301

Research Site

Lublin · Poland

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2302

Research Site

Poznan · Poland

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2303

Research Site

Płock · Poland

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2304

Research Site

Rzeszów · Poland

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2305

Research Site

Szczecin · Poland

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2306

Research Site

Warsaw · Poland

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2307

Research Site

Wroclaw · Poland

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2308

Research Site

Zabrze · Poland

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2309

Research Site

Levice · Slovakia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2310

Research Site

Lučenec · Slovakia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2311

Research Site

Malacky · Slovakia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2312

Research Site

Námestovo · Slovakia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2313

Research Site

Prešov · Slovakia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2314

Research Site

Rožňava · Slovakia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2315

Research Site

Svidník · Slovakia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2316

Research Site

Vinica · Slovakia

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2317

Research Site

Anyang-si · South Korea

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2318

Research Site

Bucheon-si · South Korea

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2319

Research Site

Busan · South Korea

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2320

Research Site

Changwon-si · South Korea

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2321

Research Site

Cheonan-si · South Korea

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2322

Research Site

Daegu · South Korea

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2323

Research Site

Daejeon · South Korea

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2324

Research Site

Gangwon-do · South Korea

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2325

Research Site

Goyang-si · South Korea

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2326

Research Site

Gwangju · South Korea

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2327

Research Site

Jeju City · South Korea

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2328

Research Site

Jeonju · South Korea

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2329

Research Site

Jinju · South Korea

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2330

Research Site

Seongnam-si · South Korea

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2331

Research Site

Madrid · Spain

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2332

Research Site

Santiago(A Coruña) · Spain

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2333

Research Site

Tainan · Taiwan

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2334

Research Site

Eskişehir · Turkey (Türkiye)

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2335

Research Site

Kocaeli · Turkey (Türkiye)

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2336

Research Site

Odunpazari · Turkey (Türkiye)

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2337

Research Site

Yenimahalle · Turkey (Türkiye)

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2338

Research Site

Chernivtsi · Ukraine

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2339

Research Site

Ivano-Frankivsk · Ukraine

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2340

Research Site

Kyiv · Ukraine

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2341

Research Site

Lutsk · Ukraine

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2342

Research Site

Vinnytsia · Ukraine

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2343

Research Site

Chesterfield · United Kingdom

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2344

Research Site

Chippenham · United Kingdom

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2345

Research Site

Corby · United Kingdom

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2346

Research Site

Coventry · United Kingdom

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2347

Research Site

Harrow · United Kingdom

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2348

Research Site

Hull · United Kingdom

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2349

Research Site

London · United Kingdom

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2350

Research Site

Northwood · United Kingdom

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2351

Research Site

Orpington · United Kingdom

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2352

Research Site

Poole · United Kingdom

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2353

Research Site

Rotherham · United Kingdom

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2354

Research Site

Shipley · United Kingdom

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2355

Research Site

Thetford · United Kingdom

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2356

Research Site

Trowbridge · United Kingdom

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2357

Research Site

Weston-super-Mare · United Kingdom

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2358

Research Site

Hochiminh · Vietnam

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2359

Research Site

Huế · Vietnam

1 trial

AZD0780 reduces LDL cholesterol in adults with heart disease or high cardiovascular risk.

AstraZenecaPh 3NCT07000123 ↗

2360

Parkway Medical Center

Birmingham · Alabama · United States

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2361

Jacksonville Center for Clinical

Jacksonville · Florida · United States

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2362

K2 Medical Research LLC

Maitland · Florida · United States

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3ActiveNCT06813911 ↗

2363

University of Miami Hospital

Miami · Florida · United States

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2364

Baptist Health South

Miami · Florida · United States

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2365

Inpatient Research Clinical LLC

Miami Lakes · Florida · United States

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3ActiveNCT06813911 ↗

2366

FXM Clin Res Miramar LLC

Miramar · Florida · United States

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2367

SEC Clinical Research

Pensacola · Florida · United States

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2368

University Of South Florida

Tampa · Florida · United States

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2369

FC Site Partners Miami

Winter Park · Florida · United States

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2370

American Health Network Research Dept

Muncie · Indiana · United States

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2371

Flourish Research Bowie

Bowie · Maryland · United States

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2372

Aa Mrc Llc

Flint · Michigan · United States

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2373

MyMichigan Medical Center Midland

Midland · Michigan · United States

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2374

AB Clinical Trials

Las Vegas · Nevada · United States

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2375

The Corvallis Clinic P C

Corvallis · Oregon · United States

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2376

Novartis Investigative Site

Tullahoma · Tennessee · United States

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2377

PharmaTex Research LLC

Amarillo · Texas · United States

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2378

Kelsey Seybold Research Foundation

Houston · Texas · United States

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2379

Novartis Investigative Site

Yinchuan · Ningxia · China

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3ActiveNCT06813911 ↗

2380

Novartis Investigative Site

Béziers · France

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2381

Novartis Investigative Site

Cholet · France

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2382

Novartis Investigative Site

Lille · France

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2383

Novartis Investigative Site

Montpellier · France

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2384

Novartis Investigative Site

Pessac · France

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2385

Novartis Investigative Site

Poitiers · France

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2386

Novartis Investigative Site

Stuttgart · Baden-Wurttemberg · Germany

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2387

Novartis Investigative Site

Singen · Germany

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2388

Novartis Investigative Site

Caserta · CE · Italy

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2389

Novartis Investigative Site

Grosseto · GR · Italy

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2390

Novartis Investigative Site

Pordenone · PN · Italy

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2391

Novartis Investigative Site

Legnago · VR · Italy

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2392

Novartis Investigative Site

Enschede · Netherlands

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2393

Latin Clinical Trial Center Inc

San Juan · Puerto Rico

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2394

Novartis Investigative Site

Pamplona · Navarre · Spain

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2395

Novartis Investigative Site

Castilleja de la Cuesta · Sevilla · Spain

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2396

Novartis Investigative Site

Las Palmas GC · Spain

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2397

Novartis Investigative Site

Salamanca · Spain

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2398

Novartis Investigative Site

Valencia · Spain

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2399

Novartis Investigative Site

Changhua · Taiwan

1 trial

Pelacarsen combined with inclisiran lowers lipoprotein(a) in people with established heart disease.

Novartis PharmaceuticalsPh 3RecruitingNCT06813911 ↗

2400

Clinical Study Center

Dothan · Alabama · United States

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2401

Clinical Study Center

Pomona · California · United States

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2402

Clinical Study Center

Boca Raton · Florida · United States

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2403

Clinical Study Center

Jacksonville · Florida · United States

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2404

Clinical Study Center

Winter Park · Florida · United States

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2405

Clinical Study Center

High Point · North Carolina · United States

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2406

Clinical Study Center

DeSoto · Texas · United States

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2407

Clinical Study Center

Renton · Washington · United States

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2408

Clinical Study Center

Adelaide · Australia

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2409

Clinical Study Center

Melbourne · Australia

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2410

Clinical Study Center

Sydney · Australia

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2411

Clinical Study Center

Chicoutimi · Canada

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2412

Clinical Study Center

Hamilton · Canada

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2413

Clinical Study Center

Montreal · Canada

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2414

Clinical Study Center

Québec · Canada

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2415

Clinical Study Center

Toronto · Canada

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2416

Clinical Study Center

Vancouver · Canada

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2417

Clinical Study Center

Rehovot · Israel

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2418

Clinical Study Center

Christchurch · New Zealand

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2419

Clinical Study Center

Birmingham · United Kingdom

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2420

Clinical Study Center

Edinburgh · United Kingdom

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2421

Clinical Study Center

London · United Kingdom

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2422

Clinical Study Center

Manchester · United Kingdom

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2423

Clinical Study Center

Nottingham · United Kingdom

1 trial

VERVE-102 gene-editing therapy lowers LDL cholesterol in familial hypercholesterolemia and premature coronary disease.

Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗

2424

Research Site

Glendale · California · United States

1 trial

AZD4954 treats elevated lipoprotein(a) and abnormal cholesterol levels in healthy and dyslipidemic adults.

AstraZenecaPh 1RecruitingNCT06980428 ↗

2425

Research Site

Port Orange · Florida · United States

1 trial

AZD4954 treats elevated lipoprotein(a) and abnormal cholesterol levels in healthy and dyslipidemic adults.

AstraZenecaPh 1RecruitingNCT06980428 ↗

2426

Research Site

Brooklyn · Maryland · United States

1 trial

AZD4954 treats elevated lipoprotein(a) and abnormal cholesterol levels in healthy and dyslipidemic adults.

AstraZenecaPh 1RecruitingNCT06980428 ↗

2427

Advanced Cardiovascular LLC

Alexander City · Alabama · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2428

University of Alabama Birmingham Saint Vincents Birmingham

Birmingham · Alabama · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2429

Alliance For Multispecialty Research - Daphne

Daphne · Alabama · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2430

Eastern Shore Research Institute

Fairhope · Alabama · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2431

CB Flock Research Corporation

Mobile · Alabama · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2432

Phoenix Clinical

Phoenix · Arizona · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2433

Elite Clinical Studies LLC

Phoenix · Arizona · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2434

Hero Clinical Research

Phoenix · Arizona · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2435

HonorHealth Research Institute

Scottsdale · Arizona · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2436

Lynn Institute of the Ozarks

Little Rock · Arkansas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2437

University of California San Diego

La Jolla · California · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2438

InvivoCure

Los Angeles · California · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2439

Clinical Trials Research - Sacramento

Roseville · California · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2440

Alliance Clinical Research

San Diego · California · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2441

Encompass Clinical Research

Spring Valley · California · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2442

Stanford Health Care

Stanford · California · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2443

Blue Coast Cardiology

Vista · California · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2444

Diablo Clinical Research

Walnut Creek · California · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2445

Focus Clinical Research

West Hills · California · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2446

UCHealth Memorial Central

Colorado Springs · Colorado · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2447

South Denver Cardiology Associates

Littleton · Colorado · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2448

Gandelman Cardiology, PC

Greenwich · Connecticut · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2449

ClinTrial Hamden

Hamden · Connecticut · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2450

Clearwater Cardiovascular Consultants

Clearwater · Florida · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2451

Proactive Clinical Research

Fort Lauderdale · Florida · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2452

Elite Cardiac Research Center LLC

Hialeah · Florida · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3TERMINATEDNCT07136012 ↗

2453

East Coast Institute for Research, LLC

Lake City · Florida · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2454

Columbus Clinical Services LLC

Miami · Florida · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2455

Kendall South Medical Center

Miami · Florida · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2456

Inpatient Research Clinic, LLC

Miami Lakes · Florida · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2457

Panax Clinical Research

Miami Lakes · Florida · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2458

Indago Research and Health Center

Miami Lakes · Florida · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2459

Eminat, LLC

Miramar · Florida · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2460

Suncoast Clinical Research Inc

New Port Richey · Florida · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2461

Ocala Research Institute, Inc

Ocala · Florida · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2462

Ormond Beach Clinical Research

Ormond Beach · Florida · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2463

Baptist Health Care

Pensacola · Florida · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2464

Denali Health Plant City

Plant City · Florida · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2465

FWD Clinical Research

Tamarac · Florida · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2466

Clinical Site Partners Orlando dba Flourish Research

Winter Park · Florida · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2467

Guardian Research Organization LLC

Winter Park · Florida · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2468

Emory University Hospital

Atlanta · Georgia · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2469

East Coast Institute for Research

Canton · Georgia · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2470

Northeast Georgia Medical Center Wisteria Building

Cumming · Georgia · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2471

Nsc Research

Johns Creek · Georgia · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2472

Georgia Clinical Research

Lawrenceville · Georgia · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2473

St Lukes Idaho Cardiology Associates

Meridian · Idaho · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2474

Solaris Clinical Research

Meridian · Idaho · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2475

Endeavor Health-Northwest Community Healthcare

Arlington Heights · Illinois · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2476

Christie Clinic

Champaign · Illinois · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2477

Advocate Lutheran General Hospital

Park Ridge · Illinois · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2478

Alliance for Multispecialty Research LLC - Park Ridge

Park Ridge · Illinois · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2479

MediSphere Medical Research Center LLC

Evansville · Indiana · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2480

Parkview Research Center

Fort Wayne · Indiana · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2481

Franciscan Health Indianapolis

Indianapolis · Indiana · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2482

Ascension Saint Vincent Heart Center

Indianapolis · Indiana · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2483

Cardiovascular Research of Northwest Indiana LLC

Munster · Indiana · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2484

Reid Physician Associates

Richmond · Indiana · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2485

MercyOne Iowa Heart Center

West Des Moines · Iowa · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2486

Hutchinson Clinic PA

Hutchinson · Kansas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2487

University of Kansas Medical Center

Kansas City · Kansas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2488

Midwest Heart and Vascular Specialists

Overland Park · Kansas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2489

Graves Gilbert Clinic

Bowling Green · Kentucky · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2490

Baptist Health Lexington

Lexington · Kentucky · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2491

The Research Group of Lexington LLC

Lexington · Kentucky · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2492

Heart Clinic of Hammond

Covington · Louisiana · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2493

Louisiana Heart Center

Slidell · Louisiana · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2494

Monroe Research LLC

West Monroe · Louisiana · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2495

Johns Hopkins Hospital

Baltimore · Maryland · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2496

Metropolitan Cardiovascular Consultants LLC

Beltsville · Maryland · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2497

Suburban Hospital

Bethesda · Maryland · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3TERMINATEDNCT07136012 ↗

2498

Flourish Research

Bowie · Maryland · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2499

Medstar Franklin Square Medical Center

Hyattsville · Maryland · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2500

Capitol Cardiology Associates

Lanham · Maryland · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2501

Brigham and Womens Hospital

Boston · Massachusetts · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2502

Henry Ford Health System

Detroit · Michigan · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2503

Healthy Heart Cardiology

Grand Rapids · Michigan · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2504

MyMichigan Medical Center Midland - Clinical Research Department

Midland · Michigan · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2505

Advanced Cardiology Associates

Rochester Hills · Michigan · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2506

Revival Research Institute

Southfield · Michigan · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2507

Saint Marys Medical Center

Duluth · Minnesota · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2508

Health East Cancer Care

Maplewood · Minnesota · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2509

Mayo Clinic

Rochester · Minnesota · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2510

Methodist Hospital

Saint Louis Park · Minnesota · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2511

Jackson Heart Clinic

Jackson · Mississippi · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2512

Cardiology Associates Research LLC

Tupelo · Mississippi · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2513

Sisters of Saint Mary Health Heart and Vascular Care

Bridgeton · Missouri · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2514

Kansas City Veterans Affairs Medical Center

Kansas City · Missouri · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2515

Washington University

St Louis · Missouri · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2516

Bryan Heart

Lincoln · Nebraska · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2517

Physician Research Collaboration, LLC

Lincoln · Nebraska · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2518

Excel Clinical Research

Las Vegas · Nevada · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2519

American Institute of Medical Research

Las Vegas · Nevada · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2520

Las Vegas Clinical Trials

North Las Vegas · Nevada · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2521

Renown Institute for Heart and Vascular Health

Reno · Nevada · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2522

Advanced Heart Care LLC

Bridgewater · New Jersey · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2523

Advanced Heart and Vascular Institute of Hunterdon

Flemington · New Jersey · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2524

Clinical Reseach Philadelphia Pennington

Hamilton · New Jersey · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2525

Med Clinical Research Partners - Irvington

Irvington · New Jersey · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2526

New Jersey Medcare / New Jersey Heart

Linden · New Jersey · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2527

Saint Michaels Medical Center

Newark · New Jersey · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2528

Circuit Clinical / Optum Medical Care of New Jersey

Secaucus · New Jersey · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2529

The Heart House - Washington Township

Sewell · New Jersey · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2530

CardioMetabolic Collaborative Clinic

Somerset · New Jersey · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2531

Ima Clinical Research - Warren

Warren Township · New Jersey · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2532

Albany Medical College

Albany · New York · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2533

Basil Clinical

Inwood · New York · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2534

Rasai Research

Jackson Heights · New York · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2535

Crystal Run Healthcare

Monroe · New York · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2536

Mount Sinai Queens

New York · New York · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2537

Niagara Falls Memorial Medical Center

Niagara Falls · New York · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2538

Circuit Clinical Orchard Park Family Practice

Orchard Park · New York · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2539

Hudson Valley Cardiovascular Physicians PC

Poughkeepsie · New York · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2540

Saratoga Clinical Research, LLC

Saratoga Springs · New York · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2541

Duke University Health System

Durham · North Carolina · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2542

Moses H Cone Memorial Hospital

Greensboro · North Carolina · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2543

Triad Clinical Trials, LLC

Greensboro · North Carolina · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2544

ClinCept, LLC

Kinston · North Carolina · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2545

Monroe Biomedical Research

Monroe · North Carolina · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2546

Piedmont Healthcare

Statesville · North Carolina · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2547

Accellacare Research of Wilmington

Wilmington · North Carolina · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2548

Wake Forest University Health Sciences

Winston-Salem · North Carolina · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2549

Lillestol Research LLC

Fargo · North Dakota · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2550

Aultman Cardiology Clinical Trials

Canton · Ohio · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2551

The Christ Hospital

Cincinnati · Ohio · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2552

Velocity Clinical Research - Cincinnati

Cincinnati · Ohio · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2553

Nexgen Research

Lima · Ohio · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2554

K and R Research

Marion · Ohio · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2555

Alliance for Multispecialty Research

Norman · Oklahoma · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2556

University of Pennsylvania

Philadelphia · Pennsylvania · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2557

Preferred Primary Care Physicians, Inc

Pittsburgh · Pennsylvania · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2558

Pottstown Medical Specialists Inc

Pottstown · Pennsylvania · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2559

Miriam Hospital

East Greenwich · Rhode Island · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2560

Pharmacorp Clinical Trials Inc

Charleston · South Carolina · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2561

Prisma Health Carolina Cardiology - Greenville

Gantt · South Carolina · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2562

Accellacare Charleston

Mt. Pleasant · South Carolina · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2563

Tribe Clinical Research - Spartanburg

Spartanburg · South Carolina · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2564

Erlanger Health, Inc.

Chattanooga · Tennessee · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2565

Apex Research Foundation, LLC

Jackson · Tennessee · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3TERMINATEDNCT07136012 ↗

2566

Alliance for Multispecialty Research Knoxville

Knoxville · Tennessee · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2567

Ascension Saint Thomas

Nashville · Tennessee · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2568

Parkway Cardiology Associates

Oak Ridge · Tennessee · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2569

Tennessee Center for Clinical Trials

Tullahoma · Tennessee · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2570

PharmaTex Research, LLC

Amarillo · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2571

Texas Diabetes and Endocrinology

Austin · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2572

Ima Clinical Research

Austin · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2573

Pioneer Medical Associates

Carrollton · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2574

Baylor Scott and White Heart and Vascular Hospital-Dallas

Dallas · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2575

The Heartbeat Clinic

Dallas · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2576

Cedar Health Research, LLC

Dallas · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2577

Cedar Health Research, LLC

Euless · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2578

East Texas Cardiology PA

Houston · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2579

Cardiovascular Specialists of Willowbrook

Houston · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2580

Vital Heart and Vein

Humble · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2581

Tcr Institute Llc

Kingwood · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2582

Epic Clinical Research

Lewisville · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2583

Texas Tech University Health Sciences Center

Lubbock · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2584

North Dallas Research Associates

McKinney · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2585

Revival Research Institute

McKinney · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2586

Texas Institute of Cardiology

McKinney · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2587

Southern Endocrinology Associates PA

Mesquite · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2588

Orion Medical

Pasadena · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2589

Valley Institute of Research Plano

Plano · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2590

St Davids Heart & Vascular PLLC dba Austin Heart

San Marcos · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2591

Tyler Cardiovascular Consultants

Tyler · Texas · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2592

Alpine Research Organization

Layton · Utah · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2593

Inova Cardiology - Fairfax

Fairfax · Virginia · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2594

Virginia Heart - Loudoun

Leesburg · Virginia · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2595

Bon Secours Cardiology

Midlothian · Virginia · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2596

Tidewater Physicians Multispecialty Group Clinical Research

Newport News · Virginia · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2597

Alliance for Multispecialty Research Norfolk

Norfolk · Virginia · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2598

Centricity Research

Suffolk · Virginia · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2599

Selma Medical Associates

Winchester · Virginia · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2600

Winchester Medical Center

Winchester · Virginia · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3TERMINATEDNCT07136012 ↗

2601

Western Washington Medical Group

Everett · Washington · United States

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2602

Canberra Hospital

Garran · Australian Capital Territory · Australia

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2603

Royal Prince Alfred Hospital

Camperdown · New South Wales · Australia

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2604

Novatrials

Charlestown · New South Wales · Australia

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2605

Concord Repatriation General Hospital

Concord · New South Wales · Australia

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2606

Orange Health Service

Orange · New South Wales · Australia

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2607

Wollongong Hospital

Wollongong · New South Wales · Australia

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2608

Advara HeartCare Wesley

Auchenflower · Queensland · Australia

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2609

Core Research Group Pty Ltd

Milton · Queensland · Australia

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2610

University of The Sunshine Coast Clinical Trials, Sippy Downs

Sippy Downs · Queensland · Australia

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2611

Dr Heart Pty Ltd

Woolloongabba · Queensland · Australia

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2612

Flinders Medical Centre

Bedford Park · South Australia · Australia

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2613

The Alfred Hospital

Melbourne · Victoria · Australia

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2614

Momentum Clinical Research - Sunshine

Melbourne · Victoria · Australia

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2615

Hollywood Private Hospital

Nedlands · Western Australia · Australia

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2616

Linear Clinical Research Limited

Nedlands · Western Australia · Australia

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2617

Clinitrials - West Perth

Perth · Western Australia · Australia

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2618

Centricity Research Calgary

Calgary · Alberta · Canada

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2619

Edmonton Cardiology Consultants

Edmonton · Alberta · Canada

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2620

Fraser Clinical Trials

New Westminster · British Columbia · Canada

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2621

SMH Cardiology Clinical Trials Incorporated

Surrey · British Columbia · Canada

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2622

ARC Biosystems Incorporated

Vancouver · British Columbia · Canada

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2623

Discovery Clinical Services Ltd

Victoria · British Columbia · Canada

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2624

Centricity Research Brampton

Brampton · Ontario · Canada

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2625

Circulate Cardiac & Vascular Centre

Burlington · Ontario · Canada

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2626

Cambridge Cardiac Care Centre

Cambridge · Ontario · Canada

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2627

Elevate Clinical Research KMH Missisauga

Mississauga · Ontario · Canada

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2628

Partners in Advanced Cardiac Evaluation

Newmarket · Ontario · Canada

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2629

Oakville Cardiovascular Research

Oakville · Ontario · Canada

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2630

Heart Health Institute Research Incorporated

Scarborough Village · Ontario · Canada

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2631

Montreal Heart Institute

Montreal · Quebec · Canada

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2632

Institut de recherches cliniques de Montreal

Montreal · Quebec · Canada

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2633

Centre de Recherche du Centre Hospitalier de l Universite de Montreal

Montreal · Quebec · Canada

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2634

Research Institute of McGill University Health Center - Glen Site

Montreal · Quebec · Canada

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2635

CIUSSS de l Estrie CHUS Hopital Fleurimont

Sherbrooke · Quebec · Canada

1 trial

Olpasiran reduces heart disease risk in patients with high lipoprotein(a) levels at risk for first major cardiovascular event.

AmgenPh 3RecruitingNCT07136012 ↗

2636

Lenexa Research Unit

Lenexa · Kansas · United States

1 trial

New inclisiran formulation with polysorbate 80 compared to current marketed version for safety and effectiveness in cholesterol reduction.

Novartis PharmaceuticalsPh 1RecruitingNCT07626281 ↗

2637

Cardiovasular Renal Metabolism

San Antonio · Texas · United States

1 trial

New inclisiran formulation with polysorbate 80 compared to current marketed version for safety and effectiveness in cholesterol reduction.

Novartis PharmaceuticalsPh 1RecruitingNCT07626281 ↗

2638

Salt Lake City Research Unit

Salt Lake City · Utah · United States

1 trial

New inclisiran formulation with polysorbate 80 compared to current marketed version for safety and effectiveness in cholesterol reduction.

Novartis PharmaceuticalsPh 1RecruitingNCT07626281 ↗

2639

Monash Health/ Victorian Heart Hospital (VHH)

Clayton · Victoria · Australia

1 trial

STX-1150 messenger RNA therapy silences PCSK9 gene to lower LDL cholesterol in patients with elevated cholesterol.

Monash UniversityPh 1RecruitingNCT07428473 ↗

2640

New Zealand Clinical Research (NZCR)

Christchurch · Christchurch · New Zealand

1 trial

STX-1150 messenger RNA therapy silences PCSK9 gene to lower LDL cholesterol in patients with elevated cholesterol.

Monash UniversityPh 1Opening soonNCT07428473 ↗

2641

Peking University People's Hospital

Beijing · China

1 trial

CSL300 antibody drug pharmacokinetics and safety evaluated in Chinese patients with end-stage kidney disease on dialysis.

CSL BehringPh 1RecruitingNCT07619820 ↗

2642

University of Central Florida

Orlando · Florida · United States

1 trial

Pilot study estimates prevalence of elevated lipoprotein(a) and cardiovascular risk markers in primary care adult population.

University of Central FloridaNCT07579325 ↗